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ABSTRACT 
Aims:  The objective of the study was to evaluate left ventricular (LV) strain by speckle 
tracking imaging and plasma NT-ProBNP in patients with moderate to severe aortic valve 
stenosis (AS). 
 Methods: Thirty-three patients with isolated AS with preserved ejection fraction (EF) 
and ten controls underwent assessment of symptoms, transthoracic echocardiography and 
measurement of plasma levels of NT-ProBNP.LV Strain and plasma NT-ProBNP were 
analysed to find differences and correlation with conventional echocardiographic 
parameters and clinical variables. These parameters were also studied for their strength to 
predict symptomatic status in these patients.  
Results: Global longitudinal (GLS), global area (GAS) and global radial (GRS) strains 
were lower in patients with aortic stenosis (n=33; Median -13.0,-26.0 and 
40.0 ,respectively) compared to controls (n=10; Median -20.4 ,-31.5 and 
49.5,respectively;p <0.001 ,0.02 and 0.01 respectively).GLS,GAS and GRS were also 
lower in severe AS patients (n=27 ;Median -12.6,-25.0 and – 38.0,respectively) compared 
to moderate AS patients (n=6;Medain -19.8,-32.5 and 52.5 respectively; p=0.02,0.01 
and0.03 respectively).GLS,GAS and GCS were lower in symptomatic (n=21;Median -
11.6,-25.0 and 38.0 ) compared to asymptomatic (n=12;Median -16.45,-29.5 and 47.0 
respectively; p=0.001,0.005 and 0.018 respectively) patients. Global circumferential strain 
(GCS) did not differ significantly between controls and AS patients or between subgroups 
of AS. There was a regional difference in strain with longitudinal strain in basal segments 
being decreased with preserved apical segmental longitudinal strain. Plasma NT-ProBNP 
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was higher in AS patients (Median 628.00 pg/ml) compared to controls (80.82 pg/ml; 
p<0.001). NT-ProBNP was higher in severe AS (Median 614.0 pg/ml) patients compared 
to moderate AS patients (Median 118.9 pg/ml) and symptomatic (Median 1191.0 pg/ml ) 
compared to asymptomatic (Median 118.9 pg/ml) patients. Absolute value of GLS 
correlated strongly with LV mass index (r= -0.70; p<0.001) and NT-ProBNP correlated 
strongly with LA volume index (r= 0.74; p<0.001). Log-transformed NT-ProBNP 
correlated well with GLS (r= -0.63; p<0.001).Of all the variables NT-ProBNP was the best 
predictor of symptomatic status ; cut-off of 190.95 pg/ml has sensitivity of 90.5% and 
specificity of 91.7%.NT-ProBNP cut-off for predicting severe AS was 141.50 pg/ml with 
a sensitivity of 88.9% and specificity of 83.3%.  
Conclusions: LV strain, especially GLS and plasma NT-ProBNP are affected early in 
patients with AS before the onset of symptoms and deterioration of LV function. 
Measurement of these variables to assess aortic stenosis patients may complement clinical 
and echocardiographic evaluation of these patients.  
Key words:  Aortic stenosis, Strain ,  NT-ProBNP 
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Introduction 
 
Aortic stenosis (AS) is the most frequent valvular heart disease in western 
countries and is the third most common cardiovascular disease after coronary artery 
disease and hypertension(1–3). Progressive age related degeneration of aortic valve 
is the most common cause (‘calcific’ AS) (2). The second most common etiology is 
bicuspid calcific AS, followed by rheumatic AS. Comparable epidemiological and 
clinical data from India are lacking but even with the high prevalence of rheumatic 
heart disease, isolated rheumatic aortic valve disease is uncommon, occurring in less 
than 5% (4,5). So, even in India, age related calcific AS and congenital AS are more 
common. Irrespective of the cause, the natural history of AS is characterized by a 
prolonged asymptomatic period, lasting many decades, during which progressive 
obstruction to left ventricular (LV) outflow tract occurs (1,6). According to the 
current guidelines, class I recommendations for valve replacement in severe aortic 
stenosis (AS) is largely based on the presence of symptoms in history or on exercise 
stress testing (7). Left ventricular systolic dysfunction as assessed by a reduced 
ejection fraction is the only other parameter considered in asymptomatic patients. No 
other clinical, hemodynamic, biochemical or echocardiographic parameter, has been 
adopted as a class I recommendation for valve replacement in the absence of 
symptoms (or if not undergoing other cardiac surgery) in patients with isolated aortic 
stenosis. 
     In asymptomatic AS increased afterload results in progressive left 
ventricular  hypertrophy and fibrosis, diastolic dysfunction and ultimately, intrinsic 
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myocardial dysfunction that becomes irreversible with duration (8–10). During the 
asymptomatic period, the risk of sudden death is similar to that of age matched 
general population (11). Hence, prophylactic surgery is not recommended and current 
guidelines recommend follow-up for these patients (7). There are several problems 
in this approach. First, the truly asymptomatic status is often difficult to assess, 
particularly in the elderly, who are not active (12). Patients may experience subtle 
symptoms and then unconsciously adjust activities to a level that does not produce 
symptoms and then deny symptoms (12). Exercise testing is recommended in such 
cases of severe AS with no or equivocal symptoms to decide on surgery, but is rarely 
performed in this setting, even in developed countries, as demonstrated by a survey 
of clinical practice in Europe (13).  The slight but definite risk involved in exercise 
stress testing and difficulty of performing it in the elderly are important deterrents. 
Second, patients under follow-up may not immediately present when symptoms 
develop. Once symptomatic, these patients are at significant risk of rapid 
deterioration and sudden death while awaiting surgery and operative risk increases 
with symptom severity. Fifth, there are no good predictors of rapid progression of 
severity to symptomatic status (12). Myocardial structural changes and dysfunction 
continue to occur without symptoms and intrinsic myocardial dysfunction cannot be 
detected early if only ejection fraction is used as an index of myocardial performance. 
To complicate the issues, follow up in India is not systematic, putting these patients 
at risk of adverse events.  
     On the other hand, the operative risk, particularly in elderly patients, and 
prosthetic valve–related long-term morbidity and mortality prevents operating on all 
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asymptomatic patients with severe AS  (14,15). Ideally, the decision for surgery 
should be late enough to outweigh the surgical risk and sufficiently early to avoid 
irreversible damage of the LV myocardium (14). The inter-patient variability in the 
progression of disease, the factors responsible for it and complexity of LV response 
to chronic obstruction are not completely understood (11). So a decision to operate 
in asymptomatic patients based on objective data is difficult to make. Therefore, 
newer parameters are needed to better predict the outcome in patients with AS. Risk 
stratification based on these parameters could thus help identify asymptomatic 
patients who would likely benefit from early elective surgery and at the same time 
avoid unnecessary interventions.  
     Recent advances in echocardiographic technology and identification of 
cardiac biomarkers have provided us with newer tools. Speckle tracking imaging and 
natriuretic peptides (which respond to wall stress) are the ones most commonly 
studied in the recent years in the setting of aortic stenosis. In the first place, this study 
helps in creating a cohort of patients with isolated AS in our setting and describe the 
clinical, echocardiographic and biochemical profile of these patients with particular 
reference to speckle tracking echocardiography and natriuretic peptides. Long-term 
follow up of these patients will give greater insight into the outcome, predictors of 
outcome and the role of above said parameters in this group of patients. 
 
 
 
 
6 
 
 
Aims and objectives 
 
1) To evaluate left ventricular strain by speckle tracking imaging (STI) and plasma 
NT-ProBNP with in patients with moderate to severe aortic stenosis with preserved 
LV function.  
2) To find correlation and differences between these newer parameters and 
conventional echocardiographic parameters. 
3) To find the value of these parameters to predict symptomatic status in these 
patients. 
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Review of literature 
Aortic stenosis: Etiology, pathophysiology and natural history 
There are three main causes of valvular aortic stenosis (2). The most common 
cause being calcific aortic valve disease (age related calcific AS) which has a 
prevalence of 2% in adults more than 65 years of age. It shares risk factors with 
atherosclerotic arterial disease and has similar, but not same, pathophysiological 
basis (2,16). Multiple genetic polymorphisms have been linked to calcific AS, 
including vitamin D receptor, Apo lipoproteins and lipoprotein (a), similar to 
atherosclerotic vascular disease (17–21). The next most common cause is congenital 
bicuspid aortic valve (BAV) with superimposed calcification. BAV has 2% incidence 
in general population and most, if not all, patients develop at least some degree of 
aortic valve dysfunction during their lifetime. Most patients present with aortic 
stenosis beyond 50 years of age when superimposed calcification causes significant 
stenosis. In a large series of AS patients, BAV accounted for more than half of the 
total cases and two-thirds of patients aged less than 70 years (22). Even among 
patients over 70 years of age, BAV accounted for 40% of the cases. On an average 
patients with BAV require valve surgery ten years younger than age-related calcific 
AS and is also associated with 'aortopathy' which can present as coarctation or 
aneurysm.  
Rheumatic heart disease involves aortic valve usually in conjunction with 
mitral valve involvement. Isolated aortic valve involvement is uncommon (< 5%) 
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(4,5). When AV alone is involved, it usually is a combination of regurgitation and 
stenosis with isolated rheumatic aortic stenosis (without significant mitral valve 
involvement or aortic incompetence) being a rare entity. 
Congenital valvular aortic stenosis can be unicuspid, bicuspid or tricuspid. 
Most patients with unicuspid valve present in childhood (1). Rare individuals with 
tricuspid congenital AS can present late. Other rare causes of AS are alkaptonuria 
and homozygous type II hyperlipoproteinemia (familial hypercholesterolemia) 
presenting in childhood as a part of severe diffuse atherosclerosis (2). 
Irrespective of the cause, the common pathophysiological characteristic is 
progressive obstruction to left ventricular ejection. The initial response to this 
increased afterload is replication of sarcomeres in parallel (8,23).This leads to 
increased wall thickness with normal or reduced LV diameter (concentric 
hypertrophy) and thereby reducing wall stress. Early in the disease process this 
hypertrophy is adaptive but there are limits to this adaptation. First, as the severity of 
obstruction increases a stage comes when even maximal hypertrophy cannot cope up 
with degree of obstruction and the LV function starts deteriorating ,called 'afterload 
mismatch' (8,24). In this situation the myocardial contractility is normal and if 
obstruction is relieved by surgery at the right time the ventricular function can be 
normalized. Second, the hypertrophy is inherently pathological with low capillary to 
myocyte ratio and reduced coronary flow reserve (25,26). There is also reduced 
perfusion pressure due to increased LVEDP. On the other hand the oxygen demand 
is increased due to increase in myocardial mass, systolic LV pressure and prolonged 
ejection. This mismatch causes myocardial ischemia especially in the subendocardial 
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region, even without obstructive coronary artery disease (25,27,28). Myocardial 
fibrosis starts in the subendocardium and progresses (9). In these patients, even in 
the presence of normal LV systolic function as indicated by preserved LV EF, the 
myocardial contractility is diminished and may not revert to normal even after 
surgery (27). 
Natural history of AS fits into the schema of pathophysiological events just 
discussed. In their classic paper, Ross and Braunwald described the natural history 
of AS (6). There is a prolonged 'latent period' of few decades where progressive 
obstruction and adaptation go on together and patient is asymptomatic. 
Approximately 30% of these asymptomatic patients with severe AS will develop 
symptoms within 2 years of diagnosis (11). Among those patients who remain 
asymptomatic the risk of sudden cardiac death is less than 1% per year (11). Once 
LV dysfunction sets in, either due to afterload mismatch or depressed contractility 
due to fibrosis, the patient becomes symptomatic and once the symptoms appear 
there is rapid progression to death if untreated. The average time of death after onset 
of cardiac failure, syncope and angina is 2,3 and 5 years, respectively (6).  
Echocardiographic assessment of aortic stenosis 
Echocardiography has replaced cardiac catheterization as the standard for 
assessing aortic stenosis. The conventional echocardiographic parameters that have 
been well studied and validated, with wide acceptance and recommended for 
evaluation of AS severity by current guidelines are 1)Peak aortic jet velocity 2) Mean 
transaortic pressure gradient 3) Aortic valve area by continuity equation (7). Other 
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parameters have not been well validated and adopted widely, but the technology to 
assess these has been existent for many years. They are related to changes in LA and 
LV as a consequence of AS and include LV thickness, LV mass, LA size, LV systolic 
and diastolic dysfunction parameters. With the advent of new echocardiographic 
technologies like speckle tracking imaging (STI) and 3D echocardiography (3DE) 
multiple new parameters like myocardial strain and torsion dynamics are being 
studied . 
Peak aortic jet velocity 
The forward systolic velocity across the aortic valve is measured using 
continuous wave doppler (CWD) and peak jet velocity is defined as the highest 
velocity signal obtained from any window (29). So, multiple windows should be 
examined in order to determine the highest velocity. Careful patient and transducer 
position are important as velocity measurement assumes that the flow direction and 
ultrasound beam are parallel. Deviation from these rules results in velocity 
underestimation, so it is important that intercept angle is within 15° of parallel and 
‘angle correction’ as a substitute to this should not be used (29–31). 
Mean transaortic pressure gradient 
The difference in mean systolic pressure between the left ventricle (LV) and 
aorta, or mean transvalvular pressure gradient, is another standard measure of 
stenosis severity (30,31). Gradients are calculated from velocity signal according to 
the modified Bernoulli’s equation (as 4v2 where v is velocity) and the mean gradient 
is calculated by integrating the instantaneous gradients over the total ejection period. 
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There are multiple sources of error in measuring jet velocity and transaortic 
gradient (29). They include recording of and contamination by MR jet and improper 
alignment of the jet and ultrasound beam. Any error in velocity estimation results in 
an even greater error in gradients, as pressure is exponentially related to velocity 
by  modified Bernoulli’s equation (as 4v2 ). The pressure recovery (PR) phenomenon 
can also cause overestimation of pressure gradient, especially when aortic root is less 
than 3 cm (29). 
Aortic valve area 
Doppler velocity is flow dependent (29).So for any given orifice area, velocity 
(and the calculated gradient) increase with an increase in flow across the aortic valve. 
This can overestimate AV stenosis in high flow states like anemia, thyrotoxicosis or 
other hyperdynamic conditions. Underestimation of severity can occur in patients 
with low ejection fraction or low stroke volumes due to small chamber dimensions. 
Calculation of the aortic valve area (AVA) is helpful in these abnormal flow states 
(29). Aortic valve area is calculated based on the continuity equation whose principle 
is that volume flow (product of cross-sectional area and linear velocity, AV) remains 
constant throughout the flow. So when area increases velocity decreases and vice 
versa. 
Calculation of AVA requires three measurements: 
● Aortic valve velocity time integral (AV VTI) 
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● Left ventricular outflow tract (LVOT) diameter for calculation of its area, assuming 
circular geometry 
● LVOT velocity time integral (LVOT VTI) 
Accuracy in this method depends on the accurate measurement of the LVOT 
diameter, as area is related to the diameter to the power of two (1 mm error in LVOT 
diameter measurement results in an error of about 10 % in AVA) (29). The 
measurement variability for LVOT diameter ranges from 5% to 8% (29) .Another 
factor is the assumption of geometry of LVOT to be circular.  
AS is a disease continuum, but is graded on the basis of above three parameters. 
Mild disease is characterised by a jet velocity less than 3 m/s, pressure gradient less 
than 25 mmHg, and AVA of 1.5 cm2 or more , and severe disease by a jet velocity 
more than 4 m/s, pressure gradient more than 40 mmHg, and AVA less than 1.0 
cm2.1 Moderate AS falls between these values (7,32). 
Other parameters 
There are many surrogate markers of the effect of AS on left ventricle and left 
atrium. They have been studied in multiple smaller studies but are not widely adopted 
due to various reasons. They include LV thickness, LV mass, LA size, LV systolic 
and diastolic dysfunction parameters. 
Left ventricular wall thickness and mass 
As discussed earlier, LV hypertrophy is an adaptive mechanism in aortic 
stenosis. But the degree of LV hypertrophy is poorly correlated with the severity of 
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flow obstruction in multiple studies (33–35). This is because there are factors in 
addition to the pressure overload influencing the LV response. Age, gender and 
genetic variation in the renin–angiotensin system all play a probable role (33–36). 
Studies have also shown that 10–20% of patients with severe AS do not have LV 
hypertrophy (34,37).The prognostic value of LVH in patients with AS has been 
shown to be variable. Whereas multiple smaller studies showed poor prognosis with 
increasing LV mass, Otto et al. found that echocardiographic LV mass had no 
predictive value in asymptomatic patients (38–42). LV hypertrophy is defined as the 
LV mass index > 95 g/m2 for women and > 115 g/m2  for men as measured by 
echocardiography using Devereaux formula (43). 
Global systolic function 
The traditional parameters to assess LV systolic function include 2D ejection 
fraction(EF) and fractional shortening (FS).Both these are affected late in the disease 
course of AS either due to afterload mismatch or due to fibrosis. Patients with 
reduced EF overall have poorer prognosis even after surgery. The present study 
excludes patients with obvious LV systolic dysfunction as assessed by 2D EF or FS. 
Diastolic function 
Diastolic function can be assessed by a combination of doppler and tissue 
doppler techniques (44). The parameters studied are mitral diastolic flow velocities 
(early diastolic E and late diastolic A), annular velocity as measured by tissue 
doppler, e' (septal annular or average of septal and lateral) and ratio of E and e’.  
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Diastolic dysfunction occurs early in AS. Diastolic dysfunction and elevation 
of LV end diastolic pressure (LVEDP) could explain exertional dyspnoea in patients 
with severe AS (45,46). The E/e' ratio correlates well with mean pulmonary capillary 
wedge pressure measured invasively and is a good echocardiographic correlate of 
LVEDP (47). An E/e’ ratio ≥13 is able to identify patients with a LV end diastolic 
pressure >15 mmHg with high sensitivity (93 %) and specificity (88 %). Impaired 
diastolic function is also a predictor of outcome in asymptomatic AS (47). In the 
study by Lancellotti et al., an E/e’ ratio >13.8 was able to identify a subset of patients 
at greater risk of future events, implying that the presence of severe LV diastolic 
dysfunction with elevated LV filling pressures is a marker of worse outcome in 
asymptomatic severe AS (45). In the same study using TDI, the lateral diastolic 
mitral annular velocity (e’) ≤9 cm/s was also able to identify patients at a higher risk 
of events (45). 
LA diameter, area and volume 
LA size is an indicator of chronic diastolic dysfunction and has prognostic value 
in AS (45,48). In AS, LA size increases with worsening diastolic dysfunction and 
reflects the severity and the chronicity of the increased LA pressure which in turn is 
a reflection of LVEDP. Atrial enlargement is a marker of progression of valvular 
disease, and it is directly related to increased ventricular mass in AS patients (49,50) 
. It also predicts a worse outcome in asymptomatic patients with AS (49,50). LA 
diameter, was shown to be able to predict progression of symptoms or all-cause 
mortality in patients with isolated AS and peak aortic pressure gradient ≥50 mmHg. 
In this study the left atrial diameter was an independent predictor of clinical outcome 
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(P=0.02) (other predictors were left ventricular end systolic diameter, P = 0.008, left 
ventricular septum thickness ,P = 0.01 ) , with no additional value of  transaortic 
gradient (51). The study by Lancellotti et al. showed that an LA indexed area ≥12.4 
cm2/m2 in asymptomatic patients could predict future cardiac events (45). 
Long axis function 
The ventricular wall has subendocardial and subepicardial layers with 
longitudinally oriented fibres and mid wall with circumferentially oriented fibres 
(52,53). Elevated end diastolic pressures as a consequence of AS limits perfusion to 
subendocardium and results in myocyte dysfunction (25,28). As a consequence, one 
of the first functions to be affected in AS is LV longitudinal function and assessing 
the LV longitudinal function might be a better way to identify subclinical myocardial 
dysfunction (9). At this stage of the disease LVEF is still preserved. Studies of LV 
longitudinal function confirmed that LV longitudinal systolic function is affected in 
AS, even in asymptomatic patients with preserved LVEF (54). Further, symptomatic 
patients with preserved LVEF had greater impairment of LV longitudinal systolic 
function (45,54).      
Earlier studies used M-mode assessment of mitral annulus excursion during 
systole (Mitral annular peak systolic excursion - MAPSE) as a marker of LV long 
axis function. In the study Takeda S et al., 78 patients with all grades of AS were 
included (among those with severe AS 23 were symptomatic and 11 were 
asymptomatic) (54). Compared to controls both septal and lateral MAPSE were 
lower in AS patients (p<0.0001 and p=0.002; respectively).Septal MAPSE was 
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different from controls in all grades of AS (p<0.05) whereas lateral MAPSE was 
significantly different only in severe AS (p<0.05). MAPSE was lower in 
symptomatic than in asymptomatic patients, on both the septal (0.91 v 1.08 cm, p = 
0.05) and the lateral sides (1.17 v 1.43 cm, p = 0.04). There was a linear relation 
between MAPSE and LV mass index at the septal side (p < 0.0004) but not at the 
lateral side. On multivariate analysis, septal MAPSE was independently related to 
both LV mass index (p = 0.001) and severity of aortic stenosis (p = 0.002).  
Later, tissue doppler (TDI) techniques replaced M-mode to assess mitral 
annular excursion. Lancelloti et al. studied systolic and diastolic mitral annular 
velocities with TDI (54).They followed 126 patients with asymptomatic severe aortic 
stenosis for a mean of 20 +/- 17 months. In that study, patients with asymptomatic 
AS who have impaired LV long axis function with peak s’ wave ≤4.5 cm/s and 
increased BNP levels ≥61 pg/ml are at increased risk of events. They also found late 
diastolic annular velocity (A velocity) less than 9 cm/sec was associated with excess 
risk of death, symptoms or surgery.  
M-mode and tissue doppler based assessment of mitral valve excursion were 
limited by the angle-dependency and poor reproducibility. Moreover mitral valve 
excursion is only a surrogate marker of long-axis function. With the advent of speckle 
tracking imaging or echocardiography (STI or STE) direct assessment of myocardial 
function (not just in the longitudinal plane but in different planes) is now possible 
without reliance on surrogate markers. Using speckle tracking imaging, the 
deformation of myocardium (lengthening or shortening) can be assessed as strain. 
17 
 
Speckle tracking imaging or echocardiography (STI or STE) 
Strain is a measure of deformation, expressed as a fractional change from an 
object’s original dimension (55,56).Within a deforming body, the amount of 
shortening (or stretch) in the tissue along any axis is called the normal strain and the 
amount of distortion associated with the sliding of layers relative to each other is 
called the shear strain (56). Strain rate is the speed at which this deformation occurs. 
The strain at any point in the tissue is composed of three components of normal strain 
along three perpendicular axes (x, y, z), and three components of shear strain in one 
of the three perpendicular planes (xy, xz, and yz). Therefore, for the left ventricle, 3 
normal strains (longitudinal, circumferential, and radial) and 3 shear strains 
(circumferential-longitudinal, circumferential-radial, and longitudinal-radial) can 
theoretically be used to describe deformation in three dimensions. In addition a 
combination effect of longitudinal and circumferential deformation, called area 
strain, can also be assessed. Global longitudinal strain (GLS), global circumferential 
strain (GCS) ,global area strain (GAS) and global radial strain (GRS) have been 
measured in this study.  
There are two methods for assessing deformation in a tissue. One method is to 
identify a small volume (sample volume) in the tissue and describe points coming 
into out of that volume as a function of time ,which yields strain rate (Eulerian or 
spatial description).The second is to follow a point in the tissue and define its motion 
as a function of space and time (Lagrangian or material description)(57,58).  
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Tissue doppler imaging measures strain rate and analyses Eulerian strain which 
is derived from temporal integration of the strain rate signal. It was introduced several 
years ago as a method to quantify myocardial function (59). However, tissue 
Doppler–derived strain has many limitations like angle dependency, noise 
interference, and significant intra-observer and inter-observer variability (60). 
Speckle-tracking echocardiography (STE) is a recent technology which 
analyses motion by tracking natural acoustic reflections and interference patterns. It 
tracks user-defined regions containing stable patterns that are described as 
‘‘speckles’’ (sometimes called  ‘‘markers’’, ‘‘patterns’’, ‘‘features’’, or 
‘‘fingerprints’’) (56,57,61).These Speckles are tracked from frame to frame to 
resolve  two-dimensional (2D) and three-dimensional (3D) sequences of tissue 
motion and deformation. Speckle-tracking technology analyses Lagrangian strain 
and strain rate can be calculated from the measured strain. In STE the end-diastolic 
tissue dimension is taken as the reference and represents the unstressed, initial length 
of the myocardium. So, the radial deformation can be either thickening (positive 
strain) or thinning (negative strain) of the myocardial wall; circumferential 
deformation can be either  shortening (negative strain) or lengthening (positive 
strain) of the circumference of myocardial wall in short axis  view and longitudinal 
deformation can be either  shortening (negative strain) or lengthening (positive 
strain) of myocardium in long axis (56). Because there is shortening in longitudinal 
and circumferential dimensions of LV compared to end-diastole and thickening in 
radial direction longitudinal (GLS),circumferential (GCS) and area (GAS – which is 
a combination of GLS and GCS) are negative quantities, whereas radial (GRS) is a 
19 
 
positive quantity. The negative sign only indicates direction and absolute value of 
the strain is taken into consideration for clinical purposes. Myocardial strain derived 
from STE is independent of angle and it can be used to analyse the strain in all 
directions from just apical and short axis views (56,57).  STE derived strain has been 
validated comparing it with other standard research tools for assessing strain in 
tissues, like sonomicrometry and tagged MRI (62,63). Speckle tracking–derived 
strain does not require assumption of any chamber morphology or indexing for 
chamber size .So, it has also been used for studying function of right ventricle and 
atria whose complex morphology precludes accurate assessment of function with 
available echocardiographic techniques (64–66). Studies have showed that STE 
derived strain is highly reproducible with minimal intra-observer and inter-observer 
variability.  
In aortic stenosis, as has already been discussed, patients can remain 
asymptomatic or minimally symptomatic for prolonged periods even in the presence 
of severe valvular disease, during which there is progressive adaptation of LV 
myocardium. The LV ejection fraction, however, remains preserved during this 
period. Previous studies with tissue doppler echocardiography established that LV 
systolic longitudinal strain and strain rate are decreased in patients with aortic 
stenosis even with preserved ejection fraction and improve immediately following 
aortic valve replacement (67,68). So , STE by virtue of its superior ability to detect 
longitudinal dysfunction, has the potential to detect subclinical cardiac dysfunction. 
Patients with AS may also differ in the regional pattern of myocardial 
adaptation which cannot be detected by current echocardiographic techniques. STE 
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derived strain, by assessing deformation in 3 dimensions, can give insight into this 
variability of adaptation in the LV, which could be of prognostic significance. 
Studies have shown that STE–derived longitudinal strains are reduced in severe 
aortic stenosis with preservation of radial and circumferential strains and LV torsion 
and it has been shown that after surgery strain improves in all  directions (69,70). 
In one of the first studies of STE measured myocardial strain in AS patients 
Becker et.al.  recruited symptomatic patients scheduled for aortic valve replacement 
of whom 22 patients had isolated AS (70). They measured radial and circumferential 
strain preoperatively, immediate postoperative (within 7 days) and six months later. 
In these patients there was significant improvement in both radial and circumferential 
strain immediately after surgery and continued to improve till 6 months. There was 
no healthy control group and the normal range of the values for GRS and GCS were 
not known at the time of study. They showed that, myocardial deformation 
parameters were affected by AS and change significantly after aortic valve 
replacement. 
Two studies were done on asymptomatic severe AS patients. Lafitte et al. 
studied asymptomatic patients with severe AS with echocardiography and exercise 
testing and compared with 60 normal subjects (69). They studied strain using 2D 
STE. They found that in comparison to controls, longitudinal strain was significantly 
lower in AS patients (17.8  vs 21.1, p < 0.05). There was no difference with radial or 
circumferential strain between AS patients and controls. Basal and apical 
longitudinal strains were separately analysed and found that only basal strain was 
significantly different in AS patients compared to controls (-12.4 vs -
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18.4,p<0.05).There was no difference in apical strain. This regional difference in 
strain was explained by earlier longitudinal contraction at apex compared to base 
which ends its longitudinal contraction against a closed aortic valve (71). Strain 
correlated well with parameters measuring of LV global systolic function but not 
with measures of AS severity. They calculated a cut-off value of -18% for GLS and 
-13% for basal strain to predict positive response on exercise stress test 
(sensitivity/specificity of  68/75% and 77/83% , respectively).Basal strain < |-13%| 
also significantly predicted clinical events. So despite normal EF, strain was 
significantly lower in asymptomatic patients with severe AS and there was regional 
difference in strain with basal segments involved more than the apical segments. In 
the second study by Zito et.al. fifty two asymptomatic patients with severe AS were 
prospectively followed for a mean 11 ± 7.5 months and strain was assessed (72). All 
patients had decreased GLS (-15 ± 4%) but increased circumferential strain (-22 ± 
5%).Only the GLS (p = 0.03) and was independently associated with the combined 
end point. The cut-off for GLS of < |-18%| had 96% sensitivity and 73% specificity 
for predicting events.  
Seventy three patients with severe AS (both symptomatic and asymptomatic 
were studied by Delgado et.al (73). In these patients with preserved LV EF, strain 
and strain rate data were compared with data from 40 controls (20 healthy individuals 
and 20 patients with LV hypertrophy).In contrast to Lafitte’s study (discussed above) 
there was significantly decreased values of LV strain in all three directions - 
longitudinal, radial and circumferential- compared to controls. At 17 months after 
AVR, LV strain values significantly improved in all the three directions, whereas 
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LVEF remained unchanged .The reduction of strain in all directions in contrast to 
previous study can be explained by inclusion of symptomatic patients, probably 
indicating that as strain gets affected in all directions symptoms appear.  
Arnold CT Ng et al. included a total of 420 patients with aortic sclerosis and all 
degrees of AS (symptomatic and asymptomatic) (74). Multidirectional strain was 
assessed by STE. They found a progressive stepwise impairment in longitudinal 
strain with increasing AS severity. There was no difference in circumferential 
between aortic sclerosis and mild AS but worsened with moderate to severe AS. 
Radial strain was decreased only in the presence of severe AS. Compared with 
asymptomatic patients, symptomatic patients had more impaired strain in 
longitudinal, circumferential and radial direction. 
The following conclusions can be drawn from the above studies (i) strain is 
reduced in patients with AS before onset of symptoms and with normal EF, (ii) 
longitudinal strain is the first to be affected and is reduced even in patients with mild 
AS, (iii) circumferential and radial strain are not affected in milder degrees of AS but 
are reduced as severity increases, (iv) there is probably a phase when there is 
compensatory increase in circumferential strain with reduced longitudinal strain, (v) 
basal longitudinal strain is affected before the apical longitudinal strain and as 
symptoms appear even apical strain is affected, (vi) reduced longitudinal strain 
predicts events in asymptomatic severe AS patients  and (vii) strain improves in all 
directions after surgery. 
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The definition of normal values of left ventricular strain is important for its 
widespread adaptation into clinical practice. Values of multidirectional strain in 
healthy individuals have varied in various studies. One cause for concern is the 
variation in measurements among different vendors due to differences in the software 
used to measure strain. One large meta-analysis sought to establish normal ranges of 
strain and identify factors that contribute to reported variations (75). Among 2,597 
healthy subjects from 24 studies, reported normal values of GLS varied from 15.9%  
to  22.1% (mean, 19.7% ; 95% CI, 20.4% to 18.9%). Normal GCS varied from 20.9% 
to 27.8% (mean, 23.3%; 95% CI, 24.6% to 22.1%) and GRS ranged from 35.1% to 
59.0% (mean, 47.3%; 95% CI, 43.6% to 51.0%). There was significant heterogeneity 
between studies. After analysis, only blood pressure (but not age, gender, equipment 
vendor or frame rate) was associated with variation in normal GLS values.   For GLS 
they were able to establish normal value as -19.7 ± 0.28 . Similar values for GRS, 
GCS and GAS from large populations are yet to be published. 
Three dimensional echocardiography (3DE) 
The earlier technique of 3D reconstruction from images acquired through 2D 
echocardiography has been replaced by the development of real time 3D 
echocardiographic (RT3DE) systems which can acquire images in three dimensions 
(76). RT3D echocardiography uses a transducer with ultrasound elements arranged 
in a grid fashion and acquires a pyramidal volume. Current RT3D systems use 
matrix-array transducer technology and typically contain more than 3000 imaging 
elements and improvements in transducer technology have resulted in smaller 
transducer footprint, better contrast and greater sensitivity and penetration. Three 
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acquisition modes are usually present in RT3D systems. Namely, real time (narrow), 
zoom (magnified) and wide angle. Once a 3D image is acquired, it can be sliced or 
“cropped” and can be manipulated to appropriately align the cardiac structures to 
visualize the desired structure or view within the acquired pyramidal volume (76).  
In aortic stenosis the potential uses of RT3DE can be for calculating LVOT 
area which can be used to calculate AVA by continuity equation .RT3DE can be used 
for direct tracing  of AVA (Planimetry) and assessing aortic valve morphology and 
measure LV function by 3D ejection fraction and calculating LV mass. In this study, 
RT3DE was used in acquiring images for measuring strain. A single full volume 
acquisition from apical view can be used for analysing strain by STE in all three 
directions (GLS,GCS and GRS) and also global area strain (GAS).In GE vivid E9 
ultrasound system (used in this study), compared to 2D STE , three dimensional 
echocardiography has some advantages (77,78). First, only one image acquisition is 
required. Second, unlike 2D images there is no overlap in myocardial segments 
which happens with acquisition in multiple views and generating bull's eye diagram. 
Third, all four strains can be analysed together and bull's eye diagram generated for 
each strain separately. Fourth, off plane movement, which is a problem with 2D-
STE, is not there in 3D acquisition. The major disadvantage is the larger foot print 
of the transducer and resultant poor image quality in some patients with poor 
echocardiographic windows.    
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Plasma N-Terminal Pro brain natriuretic peptide (NT-ProBNP) 
Brain (B-type) natriuretic peptide (BNP) is a 32-amino acid neurohormone 
synthesized in the ventricular myocardium. The first peptide formed in the synthesis 
of BNP is pre–prohormone BNP (Pre-ProBNP), a 134 amino acid peptide that is 
synthesized in the myocytes and cleaved to the prohormone BNP (ProBNP) of 108 
amino acids. ProBNP is cleaved by a circulating endoprotease, termed corin, into two 
polypeptides: the inactive N terminal pro-BNP (NT-ProBNP), 76 amino acids in 
length, and BNP, a bioactive peptide 32 amino acids in length (79–81).  
BNP causes natriuresis and diuresis, arterial vasodilation and antagonizes 
renin–angiotensin–aldosterone system and the sympathetic nervous system. Unlike 
BNP, NT-ProBNP has no biological activity or receptors (82). As a result, its half-
life is longer (120 min vs 20 min), it circulates in plasma in higher concentrations 
and it is less influenced by acute changes in the rate of secretion. Less than 5% of 
BNP is cleared via kidneys, whereas almost all of NT-pro-BNP is excreted by kidney 
making NT-ProBNP less reliable in the setting of renal dysfunction. BNP and NT-
ProBNP are released from cardiac myocytes in response to increases in ventricular 
wall stress (82,83). In AS increase in LV pressure and therefore an increase in LV 
wall stress contributes to elevation of natriuretic peptides observed in patients with 
AS (82,83). 
In aortic valve stenosis structural and functional changes in the ventricular 
myocardium precede symptom development by a long duration and trigger 
natriuretic peptide release (84–86). In all studies which included both BNP and NT-
ProBNP, the latter has appeared to be more powerful predictor of clinical endpoints. 
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One of the major advantages of NT-ProBNP is that it is simple, relatively 
inexpensive, reproducible and not operator dependent (87). Whereas, 
echocardiography requires trained and experienced sonographers with meticulous 
attention to the technical details (87). 
In the study by Gerber IL et al., where 74 patients with moderate to severe 
aortic stenosis (29 asymptomatic and 45 symptomatic) were compared to 100 
controls (87).They studied NT-ProBNP, ANP and BNP and found similar results 
with all three. Log transformed NT-ProBNP levels correlated moderately with the 
aortic valve area (r=0.57), LV mass index (r0.59), right ventricular systolic pressure 
(r0.59, p 0.05 for all comparisons).After adjustment for other confounding variables 
like age, sex, creatinine clearance and EF, the NT-ProBNP levels were higher in 
symptomatic patients compared to asymptomatic patients (mean 1.74 times 
higher;P0.014). NT-ProBNP was higher in patients with NYHA class II symptoms 
than those with NYHA class I symptoms (median- 105 pmol/l (889.83 pg/ml) vs 34 
pmol/l (288.14); p<0.0001). NT-ProBNP levels increased with increasing severity of 
AS. But there was no statistically significant difference in NT-ProBNP levels 
between patients with normal diastolic function, Grade I and Grade II diastolic 
dysfunction. When ROC was analysed NT-ProBNP had excellent AUC of 0.84 with 
the best cut-off of 60 pmol/l (508.48 pg/ml) for predicting symptomatic status with 
a sensitivity of of 78% and specificity of 79%.There was no difference in NT-
ProBNP levels in patients with and without angina after adjustment for dyspnea level.    
The same group followed 29 asymptomatic patients from the initial cohort with 
for 18 months (88). Overall 8 of the 29 patients developed symptoms. Patients were 
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classified to have elevated or normal NT-ProBNP at baseline based on a cut-off value 
of 50 pmol/L (423.73 pg/ml). More patients in elevated NT-ProBNP group (55%) 
developed symptoms compared to patients with normal NT-ProBNP (11%) with a 
OR of 9.6 (95% CI 2 to 64, p 0.02). After adjusting for age, peak aortic jet velocity, 
and the ejection fraction at baseline, the OR was 13 (95% CI 1 to 164, p 0.05). Based 
on serial peptide measurements, they concluded that in many patients there is a time 
lag of 1 year between increase in NT–ProBNP above the normal range and 
development of symptoms.  
The study of Bergler-Klein et al. included 130 patients (87 symptomatic and 43 
asymptomatic) with severe AS and followed them for a mean 370 ± 150 days (12).In 
contrast to Gerber et.al there was no significant difference in NT-ProBNP between 
NYHA class I and NYHA class II patients. This was explained by inclusion of only 
severe AS patients in this study as compared to inclusion of moderate AS patients in 
Gerber et.al. study. They showed that patients with severe AS and NT-ProBNP levels 
<80 pmol/l (677.97 pg/ml) were unlikely to develop symptoms during a nine months 
follow-up period, having a symptom free survival 88% at 9 months and 69% at 12 
months.43 However, patients with NT-ProBNP above these cut-off value had a 
symptom free survival of 35% at 9 months and 12% at 12 months. Seventy nine 
patients eventually underwent surgery and NT-ProBNP independently predicted 
postoperative outcome. 
There are three other studies which used BNP instead of NT-ProBNP, but the 
results were similar. In the study by Lim et al. which included 70 patients with severe 
AS (17 asymptomatic and 53 symptomatic) and followed them for a mean of 308 
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days, high BNP levels were significantly associated with poor outcome in 
asymptomatic patients with severe AS and BNP levels were highly accurate to 
predict symptomatic status in these patients (89). Lanceolloti et al. studied 126 
patients with asymptomatic severe aortic stenosis over a period of 20 months +/- 17 
months (45). In that study, patients with asymptomatic AS who had  increased BNP 
levels were at increased risk of events. Monin et al. developed a risk score after 
prospectively following 107 asymptomatic patients with moderate to severe AS 
(90).They further validated the score in another cohort of 107 patients. They showed 
that the combination of serum BNP levels with female sex and Vmax (Monin’s score 
= [peak velocity (m/s)×2]+ [ln BNP (pg/ml) ×1.5]+ 1.5 (if female sex)) can help 
discriminate between patients who will experience cardiac events during a two year 
follow-up and those who will not.46 For score values less than 11, a low event rate 
was found (<10 %), whereas score values above 16 were associated with higher event 
rate (>75 %).  
From the above studies it can be concluded that (i) NT-ProBNP levels increase 
with increasing severity of AS,(ii) levels are significantly higher in symptomatic 
patients compared to asymptomatic patients ,(iii) levels increase modestly from mild 
symptoms to moderate symptoms and markedly from moderate to severe symptoms, 
(iv) levels significantly predict events and (v) NT-ProBNP levels are independent 
predictor of postoperative outcome.   
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Material and methods 
Setting: 
The study was carried out in the Christian Medical College, Vellore (CMC). 
Patients were recruited from 
1) Patients visiting outpatient services in the Department of Cardiology and 
2) Patients admitted in Cardiology and Cardiothoracic wards. 
The study was started from January 2014 and was continued till January 2015. 
Data collection was done during the patient’s visit to echocardiography lab as a part 
of evaluation and during patient’s stay in the hospital, by the principal investigator. 
Participants: 
Inclusion criteria: 
1) Adult patients (> 18 years of age) with moderate to severe valvular aortic stenosis 
diagnosed by echocardiogram were eligible for the study. 
Exclusion criteria: 
1) Concomitant mitral valve disease - more than mild mitral stenosis or regurgitation 
as defined by current echocardiographic criteria 
2) Significant aortic incompetence - more than mild associated AR as defined by 
current echocardiographic criteria 
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3) Past history of acute coronary syndrome or regional wall motion abnormality of 
LV on echocardiography 
4) Past coronary or valvular surgery or percutaneous intervention 
5) Patients other than sinus rhythm 
6) LV systolic dysfunction defined as EF< 50% 
7) Renal dysfunction - estimated GFR less than 30ml/min or patients on dialysis. 
8) Pregnancy 
Sample size: 
This study looks at the speckle tracking imaging derived left ventricular strain 
and NT-ProBNP in patients with aortic stenosis. The resource limiting variable in the 
present study was the cost of NT-ProBNP. So sample size calculation was done based 
on the data about NT-ProBNP in predicting symptomatic status and outcomes. Based 
on the data from Ivor Gerber et.al (Circulation 2003; 107:1884-18L (949.15 pg/ml) 
in asymptomatic and symptomatic patients, respectively. The interquartile ranges 
were 16 to 58 pmol/l (135.59 to 491.53 pg/ml) and 71 to 93 pmol/l (601.70 to 788.14 
pg/ml )in asymptomatic and symptomatic patients, 90) (87) the median plasma NT-
Pro BNP levels were 33 pmol/L (279.66 pg/ml) and 112 pmol/respectively. The 
estimated SD was 28 pmol/l (237.29 pg/ml) in asymptomatic group and 78 pmol/l 
(661.02 pg/ml) in symptomatic group. Keeping alpha error at 5% and beta error at 
10%, the sample size needed was calculated as 12 symptomatic and 12 asymptomatic 
patients. As we derived SD from the range of values provided in the study, there 
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would have been some over or underestimation in standard deviation. Moreover, as 
this is an institution based study, the symptomatic patients are likely to be much more 
common than asymptomatic patients. Considering these issues, we studied patients 
presenting between Jan/2014 and Jan/2015 (up to 50 patients), anticipating 20-25 
patients in each group. We were able to recruit 33 patients in the given time period. 
In the present study plasma levels of NT-ProBNP were compared across the 
groups of patients with aortic stenosis. However, the mean and distribution of serum 
NT-ProBNP in normal Indian population is not known. To make the comparisons 
meaningful, an estimate of the normal value for the NT-ProBNP in our population 
was required. So a control population of 10 subjects provided an estimate of the 
normal value. Ten age and sex matched controls were selected from healthy relatives 
of patients coming to this hospital. 
Data sources and measurements: 
(I) History, physical examination and echocardiography was done by the principle 
investigator and data was collected with the help of a raw data collection sheet and 
Echocardiography pro forma. 
(II) Echocardiography 
All patients underwent echocardiography with GE vivid 9E ultrasound system. 
Two transducers were used. 
M5S-D: a phased array transducer with a frequency range of 1.5-4.6 was used 
for M-mode, 2D and doppler imaging. 
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4V-D: a volume phased array transducer with a frequency range of 1.5–4.0 
MHz was used for full volume acquisition. 
A) Two dimensional and doppler echocardiography 
Two and three dimensional grey scaled images were stored in cineloop and 
analysed offline. All standard measurements were done according to 
recommendations by ASE/ESE. End-diastolic and systolic interventricular septal 
thickness (IVSd and IVSs), LV internal diameter (LVEDD and LVESD) and 
posterior wall thickness (PWd and PWs) were measured in 2D in PLAX view. LV 
mass was calculated automatically by the system using Devereux formula and 
indexed by the body surface area to derive LV mass index. Left ventricular outflow 
tract (LVOT) diameter was measured in PLAX view parallel to the aortic annulus at 
the junction of bright and dark regions indicating septal endocardial and aortic 
annular tissue junction (as recommended by ASE /ESE). Aortic valve was imaged in 
SAX view at the level of the valve. The LV end-diastolic and end-systolic volumes 
were measured from the apical two- and four-chamber views, and LVEF was 
calculated using the biplane Simpson’s method. Similar method was used to 
calculated left atrial volume and was indexed to BSA. Left ventricular diastolic 
function was evaluated using transmitral early (E-wave) and late (A-wave) diastolic 
inflow velocities, the E/A ratio and the deceleration time obtained from the pulsed-
wave Doppler recordings. Tissue Doppler echocardiography was performed and 
peak early diastolic mitral annular velocity (e') was measured on the septal side and 
lateral side and average was calculated. E/e' was calculated by using medial e' and 
average e' (Both correlated excellently. So E/e’ using medial e’ was analysed in this  
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study). Aortic valve flow velocities were measured with continuous doppler in apical 
5-chamber (A5C), apical 3-chamber (A3C or APLAX) and when satisfactory 2D 
images were feasible doppler velocities were measured from suprasternal and right 
parasternal views. The maximum velocity in any view was taken as the aortic valve 
Vmax and the doppler spectral pattern was traced to get mean velocity and aortic 
valve velocity time integral (AV VTI).Peak and mean gradient was automatically 
calculated by the system from the measured velocities using modified Bernoulli 
equation (4v2). Pulse wave doppler of left ventricular outflow tract (LVOT) was 
acquired from apical 5 chamber view with the sample volume moved proximally 
from the level of the aortic annulus until a clear signal was obtained, usually 0.5–1 
cm below the valve. The spectral pattern was traced to measure LVOT VTI. Aortic 
valve area was calculated by the online software by continuity equation using the 
above data. For LVOT diameter, AV VTI and LVOT VTI, an average of three 
measurements was taken. 
B) Speckle tracking imaging 
Vivid 9E system has two software tools available to assess LV strain (77). 
Longitudinal strain can be assessed using automated functional imaging (AFI) 
software and strain in all directions (Longitudinal, circumferential, area and radial) 
can be calculated by using 3D images acquired with a 4V-D transducer and analysed 
with 4D automated LV quantification (4D-auto LVQ) software. 
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(i) Automated functional imaging (AFI)  
AFI is a software tool used for regional assessment of 2D longitudinal strain 
which calculates myocardial deformation based on 2D grey scale loops. AFI is 
performed in apical views in the following order: apical long-axis, 4-chamber and 2-
chamber views following an onscreen guided workflow (Fig.1) .The apical views  
            Fig. 1. 
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may be acquired sequentially in 2D mode or simultaneously in tri-plane with a 3D 
transducer. After acquisition of the grey scale loops analysis can be done off-line. 
The frame rate should be 40-80 fps (higher if HR is high) and care should to be taken 
such that the entire myocardium is visible. It is important to acquire all apical views 
sequentially to get similar heart rate in all three views (77,91).In each view, region 
of interest (ROI) is defined by placing 2 points at the base near the mitral annulus 
and one at apex following the order shown onscreen and these points trigger the 
automatic process by which the software detects the borders (Fig.2) . The ROI         
              Fig. 2                   
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 can be manually adjusted by moving the borders. The system shows preliminary 
images and the operator can assess tracking quality and if the tracking is poor, 
analysis for that view is repeated after readjusting the endocardial tracing until a 
better tracking is achieved. Inadequately tracked segments are automatically 
excluded from analysis (Fig.2). If more than 2 segments are not adequately tracked, 
longitudinal strain from that view is not calculated. The process is repeated for all 
three apical views. At the end, the longitudinal strains for each individual segment 
are displayed as curves as a function of time (Fig. 3). At the end, the average of peak 
systolic longitudinal strain of individual LV segments in each view (GLS_LAX,  
                                                                                                                                 
Fig. 3 
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GLS_A4C,GLS_A2C) and average of all views (GLS_Avg) is given. The results of 
all 3 planes are also combined into a single colour coded bull’s-eye summary (Fig.4) 
, which presents the peak systolic longitudinal strain of each segment along with a 
global longitudinal strain value for the LV (77,91). 
        
 Fig.4 
(ii) 4D- automated LV quantification (4D-Auto LVQ) 
4D-Auto LVQ is a post-processing software tool for analysing LV volumes, 
LV mass and strain using a single 3D image acquired with a 4V-D transducer from 
apical view (77,78). Region of interest (ROI) is defined manually by placing 3 points 
on the endocardial border , two at the base and one at apex .The system automatically 
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demarcates endocardial and epicardial borders, which can be adjusted manually (Fig. 
5). As a first step, end-systolic and end-diastolic frames are used to calculate LV 
volumes and 3D EF. Second step calculates LV mass by following similar method. 
 
Fig. 5 
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4D Strain analysis is integrated as the last step in the 4D Auto Left Ventricular 
Quantification tool. The meshes (segmented regions between endocardial border and 
epicardial borders) created for measuring LV volume and LV mass are re-used for 
the 4D Strain ROI (Fig.5). The 4D Strain ROI is automatically  generated in the end-
systolic frame and is built up from an endocardial and an epicardial mesh already 
used for assessing 3D EF and LV mass. The user can correct the ROI shape by 
placing attractor points to pull the nearby ROI border towards where the user wishes 
it to go. The frame rate has to be above a minimum level of at least 40% of the heart 
rate and care should be taken to check proper tracking (78). The user interface allows 
the user to reject segments with sub-optimal tracking. The  
Fig.6 
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results for these segments will then be removed. Furthermore, global strain values 
will not take these into the calculation and if more than three segments are rejected, 
global strain values will not be calculated. From the tracking results, 4D Strain 
derives longitudinal, circumferential, area and radial strain. The calculated 
parameters are presented in various ways, including a colour coded bull’s eye plot 
(Fig.6). The ventricle is divided into 17 segments, and the instantaneous strain 
throughout the cardiac cycle is displayed numerically and using colour coding in the 
bull’s eye plot . Care should be taken when comparing 2D AFI and 4D Strain, as the 
strain values in 2D AFI are the peak systolic values, including positive peaks, while 
in 4D Strain it is the strain values from the current frame, typically the end systolic 
frame, that are used. Bull’s eye plots for GCS, GAS and GRS can also be generated 
after GLS is done (Fig.7). 
 
Fig. 7 
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In this study as 2D images from apical vies were consistently of good quality 
2D-STE derived GLS was used for analysis. GCS,GAS and GRS were measured 
using 4D-Auto LVQ. 
3) Plasma NT-ProBNP 
The sample was collected at the entry into study after consent. Two to three 
millilitres of blood was collected in a lithium heparin tube after patient in recumbent 
position for at least 1 hour (this time was utilized for interview and 
echocardiography) and was sent to the department of Biochemistry for quantitative 
analysis of plasma NT-ProBNP .NT-ProBNP assay is an automated, double 
incubation sandwich assay (Roche diagnostics). In the first incubation, patient 
specimen NT-ProBNP antigen reacts with biotinylated monoclonal sheep NT-
ProBNP antibody and monoclonal NT-Pro BNP antibody labelled with ruthenium 
complex. During the second incubation, streptavidin labelled micro particles are 
added. This results in a complex bound to the solid phase via biotin-streptavidin 
interaction. The resulting reaction mixture is aspirated into the measuring cell .The 
micro particles are magnetically captured onto the surface of an electrode. Unbound 
substances are washed away. Then a voltage is then applied to the electrode, which 
induces chemiluminescent emission from bound ruthenium that is measured by a 
photomultiplier (Electrochemiluminiscense immuno assay - ECLIA). Results are 
calculated by comparing this measurement against the calibration curve.(Kit from 
Roche Diagnostics Corporation. Instrument COBAS E 411). 
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Statistical methods: 
Continuous variables were scrutinized for normal distribution using histograms 
and box-whisker plot. They were expressed mostly as mean ± standard deviation. 
When the data was skewed, median and interquartile ranges were reported. As some 
variables were skewed and number in each subgroup was small, non-parametric tests 
were used. For comparison between two groups Mann-Whitney U test and between 
more than two groups Kruskal-Wallis test war used. Categorical data were expressed 
as numbers and percentages and comparison between groups was done using Fisher's 
exact test. For correlation between continuous variables Pearson’s correlation 
coefficient was used. 
All data was entered on Microsoft Excel 2010 spreadsheets and then Statistical 
analysis was performed using SPSS software version 16.0. A P-value 0.05 was 
considered statistically significant. 
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Results 
Thirty three patients with aortic stenosis were recruited during the period. Ten age and sex 
matched healthy subjects were taken as controls.  
Age and sex: 
The mean age of the patients was 53.2 years with a standard deviation of 13.7 years, median 
of 54 years and a range 26-77 years .The patients comprised of 25 (76%) males and 8 (24%) 
females. Mean age of control population was 46.6 ± 16.2 years with a median of 47.5 and a range 
of 26 - 74 years. There were 7 (70%) males and 3 (30%) females in the control group. Symptomatic 
patients were older compared to symptomatic patients (57.2 vs 46.1 years).  
 
Associated conditions: 
Seven (21%) of the patients had type 2 diabetes mellitus. Ten (37%) patients had 
hypertension and twelve (36%) patients were either smokers or ex-smokers. They did not differ 
significantly between asymptomatic and symptomatic patients. 
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Table.1 gives the distribution of clinical variables in the patient and control population. 
 Total patients  
  (n = 33) 
Moderate AS 
  (n = 6) 
Severe AS  
(n = 27) 
 
Controls  
(n= 10) 
Age (yrs) 53.2 ± 13.7 47.3 ± 11.2 54.4 ± 14.0 46.6 ± 16.2 
Sex     
   Male     n(%) 25 (76) 4 21 7 (70) 
   Female   n(%) 8 (24) 2 6 3 (30) 
BSA (m2) 1.71 ± 0.18 1.68 ± 0.23 1.72 ± 0.18 1.75 ± 0.17 
Systolic BP (mmHg) 126.6 ± 20.4 116.8 ± 14.2 128.8 ± 21.2 126.2 ± 9.5 
Diastolic BP (mmHg) 74.9 ± 9.1 75.8 ± 11.8 74.7 ± 8.7 76.2 ± 4.4 
Heart rate (bpm) 77.6 ± 13.4 74.5 ± 8.6 78.3 ± 14.3 76.0 ± 15.5 
Creatinine clearance (ml/min) 85.1 ± 19.9 95.2 ± 19.1  82.9 ± 19.7 90.3 ± 28.8 
Hypertension    n (%) 10 (30) 0 10 - 
Diabetes mellitus    n (%) 7 (21) 1 6 - 
Smoking       n (%) 12(36) 1 11 - 
Symptoms     
    Dyspnea    n(%) 21 (64) 1 20 - 
    Angina     n(%)   6 (18) 1 5 - 
    Syncope    n(%) 1 (3) 0 1 - 
* Values are mean ± standard deviation 
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Creatinine clearance (eGFR): 
Mean creatinine clearance was 85 .13 ± 19.9 ml/min in the patients and was similar in the 
controls with a mean of 90.30 ± 28.80 ml/min. Patients with eGFR less than 30ml/min were 
excluded from this study. There was no significant difference in creatinine clearance between 
controls, symptomatic and asymptomatic patients. 
Symptoms: 
Minimally symptomatic (NYHA class I) and asymptomatic patients  were grouped together 
as asymptomatic for the purpose of analysis and patients with NYHA class II or more symptoms 
were considered symptomatic. Twenty one patients (64%) were symptomatic and 12 patients 
(36%) were asymptomatic (5 patients with moderate AS and 7 patients with severe AS). Dyspnea 
was the most common symptom with all symptomatic patients having dyspnea as one of their 
symptoms. Nineteen patients (58%) had NYHA class II dyspnea and 2 patients (6%) had NYHA 
class III dyspnea. None of the patients had NYHA class IV symptoms.  
Angina was an additional symptom in 6 (18%) of the symptomatic patients with dyspnea 
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and all except one had CCS class II angina. One patient had CCS class III angina. Only one patient 
had syncope, who also had severe dyspnea and angina (class III) .Six of the symptomatic patients 
also complained of exertional palpitations. None of the patients had features of fluid overload.  
Etiology of aortic stenosis: 
Echocardiographically aortic valve was visualized in short axis to assess the morphology. 
The etiology was considered definite bicuspid aortic valve (BAV) if unequivocally visualized. When 
three cusps were visualized and calcification at the base was seen in appropriately aged patient, 
it was considered age related calcific AS. Rheumatic involvement of mitral valve along with 
commissural fusion in AV was considered rheumatic AS (RHD). When the patient has undergone 
surgery (as was the case in 3 patients) the pathological diagnosis was considered definitive for 
the etiology. When the valve leaflets are not properly visualized or the etiology was not clear, it 
was labelled as 'uncertain/others’. Two of these patients were less than 50 years with tri-leaflet 
aortic valve and minimal calcification, probably congenital aortic stenosis with three leaflets. 
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BAV was the most common cause with 14 (42%) patients. Eleven (33%) patients had age 
related calcific AS and 2(6%) patients had rheumatic heart disease with isolated aortic stenosis 
(they had thickened and deformed mitral valve leaflets with mild or no MS or MR).In 6 (18%) 
patients the cause was uncertain.  
Echocardiographic variables: 
Table 2. Shows the echocardiographic variables in patients and controls 
 Total patients 
(n=33) 
Moderate AS 
( n= 6) 
Severe AS 
(n=27) 
Controls 
(n=10) 
IVST (cm) 1.47 ± 0.31 1.22 ± 0.44 1.52 ± 0.24 0.96 ± 0.17 
PWT (cm) 1.43 ± 0.30 1.18 ± 0.47 1.49 ± 0.22 0.96 ± 0.14 
LV EDD (cm) 4.15 ± 0.57 4.18 ± 0.76 4.14 ± 2.75 4.04 ± 0.50 
LV ESD (cm) 2.26 ± 0.56 2.77 ± 0.69 2.75 ± 0.54 2.75 ± 0.36 
LV EDV (ml) 88.94 ± 33.11 84.00 ± 22.67 90.04 ± 35.26 73.90 ± 18.63 
LV ESV (ml) 34.73 ± 16.00 30.33 ± 12.03 35.70 ± 16.80 27.90 ± 7.48 
LV EF (%) 61.61 ± 6.17 64.50 ± 7.89 60.96 ± 5.71 62.40 ± 3.69 
LA volume index 
( ml/m2  ) 
26.5 ± 9.48 27.58 ± 15.02 26.26 ± 8.18 19.26 ± 4.68 
LV mass index 
( ml/m2  ) 
129.76 
± 51.16 
113.28 
± 80.88 
133.42 
± 43.44 
64.84 
± 15.72 
LVOT diameter (cm) 2.07 ± 0.29 2.08 ± 0.19 2.06 ± 0.31 2.05 ± 0.21 
* Values are mean ± standard deviation 
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Table 2. Continuation 
 Total patients 
(n=33) 
Moderate AS 
( n= 6) 
Severe AS 
(n=27) 
Controls 
(n=10) 
Mitral valve     
E/A 0.92 ± 0.32 1.08 ± 0.17 0.88 ± 0.34 1.35 ± 0.34 
Deceleration time 
(msec) 
209.58  
±74.80 
211.67 
±12.9 
209 
±60.60 
186.00 
±20.67 
Medial e' 0.05 ± 0.02 0.07 ± 0.02 0.04 ± 0.01 0.10 ± 0.02 
E/e' 19.26 ± 9.91 1.08 ± 0.17 19.81 ± 9.88 8.78 ± 2.07 
AV Vmax ( m/sec) 4.39 ± 0.73 3.43 ± 0.20 4.60 ± 0.62 1.12 ± 0.14 
AV mean gradient 
(mmHg) 
49.68 
±18.41 
28.97 
±2.50 
54.29 
±17.17 
2.62 
±0.51 
AV VTI (cm) 98.06  
±24.54 
74.15 
±4.60 
103.37 
±24.00 
23.88 
±3.36 
LVOT VTI (cm) 23.79 ± 5.00 26.85 ± 4.90 23.11 ± 4.85 22.63 ± 3.57 
AVA index ( cm2/m2) 0.50 ± 0.15 0.73 ± 0.14 0.45 ± 0.09 1.8 ± 0.32 
* Values are mean ± standard deviation 
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Aortic stenosis severity: 
Twenty seven (82%) patients were classified as severe aortic stenosis (AVA < 1.0cm) and 6 
(18%) had moderate AS. Two patients had peak velocity and mean gradients just below the cut-
off values (AV peak velocities -3.88 and 3.80 m/sec, AV mean gradient - 36.85 and 36.33 mmHg) 
but AVA less than 1cm2 by continuity equation (AVA -0.7 and 0.6 cm2).Both of them had small LV 
volumes with stroke volume index of < 35ml/m2 (SVi - 30.6 and 33.7 ml/m2).These two patients 
had low-flow, low-gradient AS with preserved LV EF. 
1) LV mass:  
The mean LV mass indexed to BSA was 129.76 ± 51.16 gm/m2 in patients and             
64.84 ± 15.72 gm/m2 in controls. The distribution was positively skewed with a median of 135.86 
gm/m2 and a range of 56.31 to 274.55 gm/m2. Seventeen of the 27 patients with severe AS had 
LV hypertrophy as defined by ASE criterion of > 95gm/m2 in females and >115 gm/m2 in males. 
All patients had concentric LV hypertrophy with relative wall thickness more than 0.42.Grouping 
severe AS patients into mild (96-108 gm/m2 in females and 116-131 gm/m2 in males), moderate 
(109-121 gm/m2 in females and 132-148 gm/m2 in males) and severe LV hypertrophy (≥ 122 
gm/m2 in females and ≥ 149 gm/m2 in males) showed 5 and 12 patients with moderate and 
severe LV hypertrophy, respectively. None of the patients had mild hypertrophy. Only one 
patient with moderate AS had severe LV hypertrophy. 
When presence of LV hypertrophy was analyzed according to symptomatic status the most 
important difference was that only 20% of patients without hypertrophy were symptomatic 
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compared to all (100%) of patients with hypertrophy (p<0.001).  
 
LV mass index was significantly higher in severe AS group compared to controls (Median - 
144.1 vs 66.11 gm/m2; p<0.001) but there was no statistical difference between moderate AS 
and control groups (median 144.1 vs 92.36; p=0.123). 
LV mass index was significantly higher in patients with symptomatic AS compared to  
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asymptomatic AS (Median -152.55 vs 92.70 gm/m2; p< 0.001).But the correlation between LV 
mass index and AVA index was only moderate (r=-0.54, p<0.001). 
 
2) Ejection fraction:  
The mean ejection fraction (EF) in patients was 61.6 ± 6.2 % and in controls it was 62.4 ± 
3.7 %. There was no statistically significant difference between controls and patients with 
moderate or severe AS. EF was slightly lower in symptomatic patients as compared to 
asymptomatic patients (59.95 vs 64.50; p=0.037). 
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3) LA volume  
The mean LA volume indexed to body surface area was 26.5 ± 9.48 ml/m2 in AS patients 
and 19.26 ± 4.68 ml/m2 in controls. The distribution of LA volume index was also positively 
skewed with a median of 24.1 ml/m2 and a range of 13.30 to 53.50 ml/m2. Thirteen (39%) patients 
with AS had LA enlargement as defined by ASE criterion of > 28ml/m2.Six patients had mild       
(29-33ml/m2), 4 patients had moderate (34-39ml/m2) and 3 patients had severe LA enlargement 
(≥ 40ml/m2). LA volume was significantly higher in patients compared to controls (Median- 24.1 
vs 18.1 ml/m2; p=0.036) but there was no difference between moderate and severe AS groups. 
There was also no difference in LA volumes between controls and asymptomatic patients 
(Median 18.1 Vs 18.6; p= 0.692).LA volume was also higher among symptomatic patients 
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compared to asymptomatic patients (Median - 28.7 vs 18.6 ml/m2 ; p<0.001).LA volume index 
correlated moderately with LV mass index (r=0.60 ; p<0.001) and E/e' (r=0.57;p=0.001). 
 
4) LV diastolic function:  
The mean ratio of early and late mitral inflow velocities (E/A) was 0.92 ± 0.32 in patients 
and 1.35 ± 0.34 in controls. The mean deceleration time (DT), medial annular velocity (e') and 
ratio of early inflow velocity to medial annular velocity (E/e') were 209.58 ± 74.80 msec, 0.05 ± 
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0.02 and 19.26 ± 9.91 in the patient group, respectively. Corresponding values in controls were 
186 ± 20.67, 0.10 ± 0.02 and 8.78 ± 2.07. 
Twenty eight (85%) of patients had some degree of diastolic dysfunction. Among 6 patients 
with moderate AS, 4 had normal diastolic function, and 1 each had grade I and II diastolic 
dysfunction. Almost all patients with severe AS had diastolic dysfunction. Among 27 patient with 
severe AS 12 patients had grade I, 13 patients had grade II and 1 patient had grade III diastolic 
dysfunction. Among controls, 2 patients over 50 years had grade I diastolic dysfunction.  
 
 
All symptomatic patients had diastolic dysfunction (8 had grade diastolic dysfunction and 
13 had grade II or more).In contrast only 7 (58%) of asymptomatic patients (5 grade I and 2 grade 
II) had diastolic dysfunction .The proportion of patients with LV hypertrophy between 
symptomatic and asymptomatic patients was statistically significant (p =0.003). 
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E/e', which is an indirect indicator of LV filling pressure was significantly higher in patients with 
AS compared to controls (Median -16.98 vs 9.22; p < 0.001).There was no statistically significant 
difference between moderate and severe AS groups (Median - 11.27 vs 17.09; p=0.199).E/e' was 
significantly higher in symptomatic patients compared to asymptomatic patients (Median- 21.58 
vs 12.10; p<0.001). 
 
5) LV strain 
Global longitudinal strain (GLS), global circumferential strain (GCS), global area strain 
(GAS) and global radial strain were measured. From the longitudinal strain of individual segments 
basal and apical average segmental strain was calculated. The distribution of echocardiographic 
variables among symptomatic and asymptomatic and asymptomatic patients is given in Table.3.  
The mean ± SD and median values of strain are given in the Table 4. Distribution of various strain 
values in patients with AS is shown in the histograms. 
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Table.3 Distribution of echocardiographic variables according to symptoms 
 Asymptomati
c patients 
(n=12) 
Symptomatic 
patients 
(n=27) 
P value * 
 
Age (yrs) 46.08 ± 12.35 57.19 ± 12.99 0.03 
Sex    
Male   ( n) 8 17 ns 
Female   (n) 4 4 ns 
BSA (m2) 1.72 ± 0.18 1.70 ± 0.19 ns 
Systolic BP (mmHg) 
122.08 ± 
17.82 
129.24 ± 
21.79 
ns 
Diastolic BP (mmHg) 73.67 ± 9.23 75.62 ± 9.18 ns 
Heart rate (bpm) 78.3 ± 12.8 77.2 ± 14.1 ns 
Creatinine clearance 
(ml/min) 
93.82 ± 19.93 80.16 ± 18.54 ns 
Hypertension (n) 2 8 ns 
Diabetes mellitus (n) 2 5 ns 
Smoking (n) 4 8 ns 
IVST (cm) 1.22 ± 0.23 1.61 ± 0.25 <0.001 
PWT (cm) 1.17 ± 0.24 1.59 ± 0.27 <0.001 
LV EDD (cm) 3.85 ± 0.37 4.32 ± 0.61 0.001 
LV ESD (cm) 2.36 ± 0.40 2.98 ± 0.51 0.001 
LV EDV (ml) 73.33 ± 21.75 97.86 ± 35.56 0.008 
LV ESV (ml) 25.67 ± 7.39 39.91 ± 17.39 0.008 
LV EF (%) 64.50 ± 5.95 59.95 ± 5.80 0.037 
LA volume index 
( ml/m2  ) 
20.05 ± 5.94 30.19 ± 9.23 0.001 
LV mass index ( ml/m2  ) 
84.10 ± 14.68 155.86 ± 
45.86 
<0.001 
LVOT diameter (cm) 1.99 ± 0.14 2.11 ± 0.35 ns 
# values are mean ±standard deviation . * ns – not significant  
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Table 3 continuation 
 
 Aymptomatic 
patients 
(n=12) 
Symptomatic 
patients 
(n=27) 
P value * 
 
Mitral valve    
E/A 0.97 ± 0.26 0.88 ± 0.35 ns 
Deceleration time 
(msec) 
206.58 ± 96.29 211.29 ± 61.99 ns 
Medial e' 0.06 ± 0.02 0.04 ± 0.01 <0.001 
E/e' 12.93 ± 7.33 22.87 ± 9.49 <0.001 
AV Vmax ( m/sec) 3.87 ± 0.52 4.60 ± 0.67 0.001 
AV mean gradient 
(mmHg) 
37.02 ± 10.58 56.92 ± 18.15 0.001 
AV VTI (cm) 80.36 ± 8.78 108.18 ± 25.02 <0.001 
LVOT VTI (cm) 25.10 ± 4.84 23.04 ± 5.05 ns 
AVA index ( cm2/m2) 0.6 ± 0.2 0.4 ± 0.1 0.048 
# values are mean ±standard deviation . * ns – not significant  
 
Distribution of various strain values in patients with AS 
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Table 4.Distribution of strain in patients and controls 
 
Total patients 
(n=33) 
Moderate AS 
(n=6) 
Severe AS 
(n=27) 
Controls 
(n=10) 
Global longitudinal 
strain (GLS) 
-13.56 ± 3.80 -17.57 ± 4.63 -12.66 ± 3.02 -20.77 ± 1.49 
Global 
circumferential strain 
(GCS) 
-16.39 ± 3.34 -18.33 ± 2.33 -15.96 ± 3.40 -16.80 ± 2.82 
Global area strain 
(GAS) 
-26.06 ± 5.04 -31.16 ± 4.31 -24.93 ± 4.51 -30.40 ± 3.60 
Global radial strain 
(GRS) 
39.70 ± 11.12 49.67 ± 10.39 37.59 ± 10.21 48.9 ± 8.54 
* Values are expressed as mean ± standard deviation and median (25th percentile to 75th percentile) 
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Table.4 continuation 
 Total patients 
(n=33) 
Moderate 
AS (n=6) 
Severe AS 
(n=27) 
Controls 
(n=10) 
Basal longitudinal 
strain 
-9.51  ±  4.28 -14.35 ± 4.82 -8.44 ± 3.39 -19.02 ± 1.22 
Apical 
longitudinal 
strain 
-16.82  ± 5.49 -19.37 ± 6.90 -16.2 ± 5.11 -23.38 ± 3.98 
NT-ProBNP 
(pg/ml)^ 
453.40 
(141.50  –
1761.00) 
118.90 
(48.06 –
1669.00) 
614.20 
(187.70 -
2141.00) 
34.63 
(20.08 - 
72.17) 
* Values are expressed as mean ± standard deviation and median (25th percentile to 75th percentile) 
 
 
Median GLS, GAS and GRS were significantly lower in patients compared to controls         
(-13.0 vs -20.4, -26.0 vs -31.5 and 40.0 vs 49.5, respectively; p<0.001, p=0.02 and p=0.018, 
respectively).Median GCS did not statistically differ between both groups (-16.0 vs -16.0, p= 
0.685). 
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Comparison between moderate and severe AS groups showed significantly lower median 
GLS,GAS and GRS in patients with severe AS compared to patients with moderate AS (-12.6 vs -
19.85 ,-25.0 vs -32.5 , 38.0 vs 52.5 ,respectively; p=0.015,p=0.011,p=0.026,respectively).There 
was no difference in GCS between severe and moderate AS patients (-16.0 vs -18.0 ; p= 0.095). 
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Among symptomatic patients median GLS, GAS and GRS were significantly lower compared 
to asymptomatic patients (-11.6 vs -16.4, -25.0 vs -29.5, 38.0 vs 47.0, respectively;             
p= 0.001, p=0.005,p=0.10,respectively.Again,GCS did not differ significantly (-16.0 vs -17.83 ; 
p=0.087).  
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GLS, GAS and GRS were also lower in patients with diastolic dysfunction compared to 
patients with normal diastolic function (median- -12.6 vs -19.2, -25.0 vs -34.0, 38.0 vs 57.0; 
p=0.012, 0.014 and 0.021, respectively).But GCS did not differ significantly in patients with 
diastolic dysfunction (Median- -16.0 vs -20.0; p=0.06).When analyzed for difference in strains 
between different degrees of diastolic dysfunction there was no significant difference (see figures 
with p values).  
 
 
Among patients, when global strain values were correlated with ejection fraction, LA 
volume index, LV mass index and E/e' only GLS showed strong correlation with LV mass  
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index (Table .5). GCS, GAS and GRS did not show any correlation or only weak correlation .GLS 
showed modest negative correlation with AVAi (r= -0.66; p<0.001). 
Table. 5 Correlation between multidirectional strain and echocardiographic variables 
 Absolute  
GLS 
Absolute 
GCS 
Absolute 
GAS 
GRS NT-ProBNP 
Ejection 
fraction 
r= 0.43 r= 0.53 
p=0.001 
r= 0.47 r= 0.52 
p=002 
r= -0.11 
LA volume 
index 
r= - 0.35 r= -0.23 r= -0.29 r= -0.25 r= 0.74 
p<0.001 
LV mass 
index 
r= -0.70 
p<0.001 
r= - 0.26 r= -0.39 r= -0.41 r= 0.68 
p<0.001 
E/e' r= -0.39 r= -0.29 r= -0.34 r= -0.31 r= 0.56 
p=0.001 
 
Absolute value of global longitudinal strain (GLS) showed strong negative correlation with 
LV mass index (r= - 0.70; p<0.001) i.e. as LV mass increased absolute GLS (ignoring the negative 
sign) decreased. Absolute value of GLS showed modest positive correlation with aortic valve area 
(r= 0.66; p<0.001) i.e. as AVA decreased absolute value of GLS decreased.  
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Pattern of longitudinal strain involvement  
Visual analysis of bull's eye diagram of longitudinal strain showed two patterns of reduced 
strain in various segments of LV myocardium. 
One common pattern was reduced strain in the basal segments, especially the basal 
anterolateral and inferolateral segments, with preserved strain in mid and apical segments .The 
second is more extensive reduction of strain. 
 
Longitudinal strain in healthy subject 
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                      Reduced longitudinal strain in basal segments 
                  More extensive reduction in longitudinal strain 
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Although subjective, the first pattern was seen in 8 of the asymptomatic patients. All of the 
symptomatic patients had the second pattern with more extensive reduction of longitudinal 
strain. Two asymptomatic patients, both with moderate AS, had near normal strain pattern. None 
of the symptomatic patients had normal strain pattern. 
Quantitative analysis of pattern of involvement was done by calculating basal and apical 
average segmental strain from the longitudinal strain of individual segments. Compared to 
controls basal longitudinal strain was significantly lower in moderate and severe AS patients 
(median -18.8 vs -16.0 vs -8.5; p<0.001).But apical longitudinal strain was not significantly 
different between controls and moderate AS (median -22.1 vs -21.3; p=0.514) and between 
moderate AS and severe AS (Median -21.3 vs -16.2; p=0.161). When symptomatic and 
asymptomatic sub-groups were analyzed there was significantly lower basal longitudinal strain 
in asymptomatic patients compared to controls (median -16.3 vs -18.8; p<0.001) and lower in 
asymptomatic patients compared to symptomatic patients (median -7.7 vs -13.2; p=0.001).But 
apical longitudinal strain did not differ between controls and asymptomatic patients       
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(median -22.1 vs -19.6; p=0.210) . Apical strain was lower in symptomatic compared to 
symptomatic patients (-15.2 vs -19.6; p=0.41). 
When analyzed between controls and sub-groups with moderate and severe AS there was 
no difference in apical longitudinal strain (Control -22.1 vs moderate AS -21.3; p=0.512 and 
moderate AS -21.2 vs severe AS -16.2; p=0.161) but basal longitudinal strain was significantly 
lower in moderate AS patients compared to controls (-16.0 vs -18.8; p=0.012) and lower in severe 
AS patients vs moderate AS (-8.5 vs -16.0; p=0.01) 
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Table 6. Strain and NT-ProBNP values in symptomatic and asymptomatic patients 
 Asymptomatic 
patients 
(n=12) 
Symptomatic 
patients 
(n=21) 
P value 
Global longitudinal 
strain (GLS) 
-16.57 ± 3.44 -11.8 ± 2.84 0.001 
Global 
circumferential 
strain (GCS) 
-17.83 ± 3.61 -15.57 ± 2.94 0.087 
Global area strain 
(GAS) 
-29.42 ± 5.20 -24.14 ± 3.90 0.005 
Global radial strain 
(GRS) 
46.92 ± 11.30 35.71 ± 8.95 0.010 
Basal longitudinal 
strain 
-12.98 ± 3.99 -7.53 ± 3.05 0.001 
Apical longitudinal 
strain 
-19.43 ± 5.55 -15.32 ± 4.99 0.041 
NT-ProBNP (pg/ml) 118.90  
(73.40 to 
174.38) 
1191.00  
(494.30 to 3844.00 ) 
<0.001 
* Values are expressed as mean ± standard deviation and median (25th percentile to 75th percentile) 
 
6) NT-ProBNP 
Distribution of NT-ProBNP was positively skewed (see figure below).So log transformed NT-
ProBNP was used when appropriate. The median NT-ProBNP was significantly higher in patients 
compared to controls (453.40 vs 34.63 pg/ml; p<0.001).Median NT-pro BNP was significantly 
higher in severe AS patients compared to moderate AS patients (614.20 vs 118.90 pg/ml 
p=0.036).  
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Compared to asymptomatic patients median NT-Pro BNP was higher in patients with 
symptoms (123.95 vs 204.97; p<0.001).Plasma NT-ProBNP was significantly higher in patients 
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with diastolic dysfunction as compared to patients with no diastolic dysfunction (median- 630.95 
vs 117.40 pg/ml; p= 0.001).NT-proBNP also increased with higher grades of LV diastolic 
dysfunction (median - 1355.00 pg/ml in grade II/III vs 264.20 pg/ml in grade I; p=0.018).  
 
When NT-ProBNP was correlated with other echocardiographic variables there was strong 
positive correlation with LA volume index (r=0.735;p<0.001). Correlation with LV mass index 
(r=0.676;p<0.001) and E/e (r=0.564;p=0.001) was modest. There was poor correlation between 
NT-ProBNP  and AVAi (r= -0.38).But log transformation of NT-ProBNP showed correlation of             
r= - 0.46;p= 0.007.  
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Scatter plot of absolute GLS and NT-ProBNP showed a modest negative linear correlation 
but suggested a stronger exponential relationship. Log transformed NT-ProBNP was analyzed and 
showed better negative correlation with absolute value of GLS (r= -0.63; p<0.001). 
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Receiver operator characteristic (ROC) curves 
When LV mass index, LA volume index, AVA index, E/e' , LV strains and plasma NT-ProBNP 
were analyzed for receiver operator characteristics to predict symptom status NT-ProBNP, LV 
mass index, E/e' and global longitudinal strain (GLS ) had best area under curves (AUCs). 
AUC for NT-ProBNP for predicting symptomatic status is 0.98 (95% CI 0.93 -1.00) .The best 
cutoff value was 190.50 pg/ml with a sensitivity of 90.5% and specificity of 91.7% to predict 
symptoms. AUC for NT-ProBNP for severe AS is 0.778 (95% CI 0.49 - 1.00).The best cut-off for 
predicting severe AS is 141.5 pg/ml with a sensitivity of 88.9% and specificity of 83.3%. 
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AUC for GLS was 0.839 (95% CI -0.71 - 0.97).The best cutoff value was -14.25 with 76% 
sensitivity and 67% specificity to predict symptom status. 
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Discussion 
We studied echocardiographic parameters including multidirectional 
myocardial strain and plasma NT-ProBNP in patients with moderate to severe aortic 
stenosis. 
The most common cause of aortic stenosis in this study was bicuspid aortic 
valve unlike in other larger studies where age-related calcific AS predominated 
(1,42). This perhaps is due to relatively younger population in this study (Mean age 
of 53.2 years compared to more than 65 years in most larger studies).As this is not a 
community based study the proportions do not reflect the relative prevalence of 
various causes. As with any hospital based study, selection bias might have been 
introduced because this is a tertiary care hospital and most individuals come for 
definitive therapy. Younger patients in their active years are ready to undergo surgery 
and present earlier (or referred earlier) compared to older individuals who present 
only when the symptoms are severe and very elderly tend to avoid surgery altogether. 
Moreover, the sample size is small for making any generalizations about the true 
proportions of each cause. Rheumatic heart disease accounted only for two cases, 
which is not surprising even with the high prevalence of RHD in India as isolated 
rheumatic aortic stenosis is rare. Although not analysed in this study, if patients with 
significant mitral valve disease or aortic incompetence are included, more than half 
of the cases of moderate to severe AS are rheumatic in etiology (see algorithm). Only 
7 patients with severe AS were asymptomatic which can also be explained by the 
selection bias discussed above. 
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As with all previous studies LV mass was only moderately correlated with 
aortic valve area (r=-0.54).When analysed as a continues variable the LV mass index 
increases as severity of AS increases but as defined by current ASE criteria for LV 
hypertrophy, there was also no significant difference in presence of LVH among 
moderate and severe AS patients. First, this lack of correlation with severity of AS 
can be explained by variability of hypertrophic response in among different 
individuals. This is because there are other factors in addition to the pressure overload 
influencing the LV response like age, gender, hypertension and genetic variation in 
the renin–angiotensin system (33,35,36). In this study 37% of patients with severe 
AS did not have hypertrophy. In previous studies this number was 10–20% (34,37). 
Second, the cut-off points of 95gm/m2 and 115gm/m2 in women and men, 
respectively, probably do not hold good for AS patients. When symptoms were 
considered, all of the patients with LVH were symptomatic and only one-fifth of the 
patients without LVH were symptomatic. Larger studies in the past also found that 
echocardiographic LV mass had no predictive value for events in asymptomatic 
patients. So, LVH is variably related to severity of AS due to multiple factors 
responsible for hypertrophy but LVH is usually present in symptomatic patients, 
probably being one of the causes of symptoms due to higher grades of diastolic 
dysfunction associated with it. 
All patients in this study had EF >50%.There was no significant difference in 
EF among patients with moderate or severe AS. The EF was slightly lower in 
symptomatic patients but the values in both groups were within normal range. The 
difference was small and so the sample size is inadequate to study any cut-off for EF 
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between symptomatic or asymptomatic patients. In larger studies there was no 
difference among symptomatic or asymptomatic patients and EF did not predict 
events among patients with EF>50-55%.Two (6%) patients in this study had features 
of low-flow, low-gradient severe AS with preserved LV function which is similar to 
reported values of 5-15%. 
LA volume index was significantly higher in symptomatic patients and 
correlated with LV mass (r=0.60) and E/e' (r=0.57).ROC curve for prediction of 
symptomatic status showed AUC of 0.865 for LA volume index with best cut-off of 
22.25 ml/m2 with a sensitivity of 90.5% and specificity of 83%.LA size is a marker 
of chronic diastolic dysfunction and as expected increases with increasing LV filling 
pressure, as shown here. Also, LV hypertrophy with its associated diastolic 
dysfunction and elevated filling pressures increases the LA size. But LA size did not 
significantly differ between controls and moderate AS and moderate to severe AS 
patients, again showing that LA size is not just dependent on the severity of AS. All 
symptomatic patients with AS had diastolic dysfunction (38% grade I and 62% grade 
II or more).Diastolic dysfunction is one of the important mechanisms which causes 
symptoms in AS patients with normal LV function. So the results were as expected. 
Global longitudinal strain (GLS),global area strain (GAS) and global radial 
strain (GRS), but not global circumferential strain (GCS) ,were decreased in patients 
with AS compared to controls decreased with increasing severity of AS. This is in 
contrast to the study by Lafitte et.al where only GLS was lower but similar to the 
results of Delgado et.al. Study by Lafitte et.al. included only asymptomatic patients 
unlike the second study ,which included both symptomatic and asymptomatic 
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patients (69,73).In our study symptomatic patients formed the majority. So a 
reasonable conclusion that can be drawn is that longitudinal strain is first affected 
and as disease progresses strain in other directions is affected and patient becomes 
symptomatic. This has been explained pathophysiologically by examining the 
orientation of myofibres in the myocardium (52,53).LV has subendocardial and 
subepicardial layers with longitudinally oriented fibres and mid wall with 
circumferentially oriented fibres. Because of increased LV pressure and ischemia, 
LV subendocardium is the most vulnerable in patients with AS and gets affected first. 
So, GLS which is a function of subendocardial fibres, is the first to reduce. The 
absence of significant difference in GCS compared to controls shows that probably 
GCS, which is a function of mid wall fibres, is the last to get affected. In fact, in the 
study by Zito et.al. the GCS was significantly elevated compared to controls probably 
suggesting a phase when there is compensatory increase in GCS (72).  
Even though GLS, GRS and GAS were significantly lower in asymptomatic 
patients compared to controls and decreased further in symptomatic patients, when 
ROC curve was analysed only GLS had good AUC of 0.839 to predict symptoms. 
Best cut-off of -14.25 had sensitivity of 76 % and specificity of 67% to predict 
symptomatic status. 
When regional strain was assessed qualitatively by examining bull's eye plots, 
most asymptomatic patients (8 of 12 patients) had reduced longitudinal strain only 
in the basal segments with normal values in apical segments. All symptomatic 
patients had more extensive reduction of strain. Quantitative analysis also showed 
similar results, with apical strain not differing significantly between controls and 
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moderate AS and controls and asymptomatic patients. Apical strain was reduced in 
severe AS patients and symptomatic patients compared to controls. So, basal strain 
was affected earlier in the course of disease and as disease progresses apical segments 
are also involved. This can be explained by experimental models which showed that 
contraction in LV starts from apex and progresses to base (71).In patients with AS 
the basal segments end their longitudinal contraction against a closed aortic valve 
and so are subjected to greater stress. This probably results in earlier involvement of 
basal strain. 
NT-ProBNP levels increased in a step wise fashion from controls as severity 
of AS increased. Same was observed between controls, asymptomatic and 
symptomatic patients. NT-ProBNP levels also increased with worsening diastolic 
function. NT-ProBNP had strong correlation with LA volume index (r=0.735) and 
modest correlation with LV mass index (r=0.676) and E/e (r=0.564).Association 
between absolute GLS and NT-ProBNP suggested an exponential relationship and 
log transformed NT-ProBNP showed negative correlation with absolute value of 
GLS (r= -0.63).This suggested that till GLS decreased to a point there was small 
elevation in NT-ProBNP and below that point there is an exponential increase. 
Observations from experimental models have shown increased synthesis and release 
of BNP once there is transition from compensated to decompensated state of LV 
myocardium (92). This transition may not be reliably measured by traditional 
echocardiographic method but probably GLS can detect the transition. To determine 
this cut-off point larger sample size is required. On ROC curve analysis NT-ProBNP 
has the best AUC (0.98) compared to any echocardiographic variable for predicting 
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symptomatic status. A cut-off value of 190.95 pg/ml has sensitivity of 90.5% and 
specificity of 91.7% to predict symptomatic status. 
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Conclusions 
So, the following conclusions can be drawn from the study 
1. Strain along longitudinal (GLS) and radial (GRS) directions is significantly 
reduced in patients with aortic stenosis with preserved LV ejection fraction compared 
to healthy subjects. Global area strain is also similarly reduced. 
2. In contrast, strain in circumferential direction (GCS) is not significantly reduced 
even in severe symptomatic patients with AS. 
3. Of all the strains, Global longitudinal strain (GLS) is the most significantly 
decreased. 
4. There is regional difference in decrease in longitudinal strain with basal 
longitudinal strain affected more than apical longitudinal strain. 
5. In asymptomatic patients with AS only basal strain is reduced with preserved 
apical strain and in symptomatic patients apical longitudinal strain is also reduced. 
6. Reduced global longitudinal strain (GLS) predicts symptomatic status in AS 
patient 
7. NT-ProBNP levels increase with increasing severity of AS even in asymptomatic 
patients 
8. NT-ProBNP levels are significantly higher in symptomatic patients compared to 
asymptomatic patients. 
9. Compared to all other echocardiographic variables, NT-ProBNP levels best predict 
symptomatic status in AS patients. 
Long term follow up of this cohort of patients will give greater insight into the 
outcome and the role of these parameters in predicting the outcome. As event rate in 
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aortic stenosis patients is low long follow up will be required. Once outcome data is 
available, analysis based on events and determining cut-offs will be more useful for 
clinical application of the results. 
 
 
Limitations 
1. Small sample size and even lesser number in sub-groups. 
2. Selection bias due the nature of patient recruitment with the usual biases of a 
nonrandomised population. 
3. Echocardiography is observer dependent and is associated with observer 
expectancy bias. Inter-observer and intra-observer variability was not measured for 
this analysis. 
4. This analysis is a cross sectional observational study and patient outcomes are not 
known. So translation into clinically meaningful data requires long-term follow. 
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Abbreviations 
 
3DE 3-dimensional echocardiography 
4D Auto LVQ 4-dimensional automatic left ventricular quantification 
A3C Apical 3-chamber view 
A5C Apical 5-chamber view 
AFI Automated functional imaging 
APLAX Apical long axis view 
AS Aortic stenosis 
ASE American Society of Echocardiography 
AV Aortic valve 
AVA Aortic valve area 
AVAi Aortic valve area index 
BNP Brain natriuretic peptide 
CWD Continuous wave doppler 
ECLIA Electrochemiluminisccence assay 
EF Ejection fraction 
ESE European Society of Echocardiography 
GAS Global area strain 
GCS Global circumferential strain 
GLS Global longitudinal strain 
GRS Global radial strain 
LA Left atrium 
LV Left ventricle 
LVEDP Left ventricular end diastolic pressure 
LVH Left ventricular hypertrophy 
LVOT Left ventricular outflow tract 
MAPSE Mitral annular peak systolic excursion systolic 
NT-ProBNP N-terminal pro-brain natriuretic peptide 
ROC Receiver operator characteristics 
ROI Region of interest 
RT3DE Real-time 3-dimensional echocardiography 
STE Speckle tracking echocardiography 
STI Speckle tracking imaging 
VTI Velocity time integral 
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Patient consent form 
 
Study Title: The role of extended Vs conventional echocardiographic parameters 
and NT-ProBNP in assessing aortic stenosis. 
 
 
Participants name: 
ID:  
Date of birth /Age:  
 
 
I ________________________ son /daughter of _____________________ 
1. Declare that I have read the information sheet provided to me regarding this study 
and have clarified doubts that I had about the study. 
2. I also understand that my participation in this study is entirely voluntary and that I 
am free to withdraw permission to continue to participate at any time without 
affecting my usual treatment or my legal rights. 
3. I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access. 
4. I understand that my identity will not be revealed in any information released to 
third parties or published. 
5. I voluntarily agree to take part in this study. 
 
 
Name:                                                                         Space for thumb impression 
Signature: 
Date: 
Name of the witness: 
Relationship to the participant: 
Date:  
xi 
 
                                  Data collection sheet 
Patient details 
 
Hospital ID:                                                                         Study ID: 
Name:                                                                                   Age:                     Sex :    
Address:                                                                       
 
Phone 1:                                                                    Phone 2: 
E-Mail: 
--------------------------------------------------------------------------------------------------------------------- 
SYMPTOMS 
Dyspnea:  
Duration -                                                                             Progression - 
Current Severity - NYHA class: 
PND -                                                                                       Orthopnea- 
Any other characteristics- 
 
Pre-syncope /syncope: 
Number -                                                                  Duration -                            
Exertional /rest -  
If syncope: Posture at onset-                                           Preceding palpitations-  
               Duration of LOC-                                             Involuntary movements-   
               Symptoms after recovery- 
Any other characteristics- 
 
Chest pain 
Character: Angina / Atypical / Non-cardiac 
If angina:  Severity - CCS class:                                    Any rest pain -                                
                 If yes - episodes/duration                               Any nocturnal angina-    
Any other characteristics- 
xii 
 
 
Palpitations: 
Duration -                                                                    Frequency- 
Exertional /rest -                                                   Duration of each episode - 
Regular or irregular-                                          Any ECG documentation -  
Any other characteristics - 
 
 
Other symptoms: 
 
Other diseases/ Past medical history: 
 
Diabetes: 
Systemic hypertension: 
Peripheral vascular disease: 
Rheumatic fever- 
 
Stroke: Ischemic/Haemorrhagic/lacunar/unknown      Site (on imaging)-                   
Clinical manifestation:   
 
TIA:                                                        GI  bleeding:                                               
Others: 
 
Smoking: Duration -                                  Number-                                  Pack years- 
           If reformed- Started -                       Quit -  
Medications:  
 
 
 
 
 
 
xiii 
 
Physical examination 
 
Height:                                                                                    BSA: 
Weight:                                                                                   BMI: 
--------------------------------------------------------------------------------------------------------------- 
Blood pressure: 
Arterial pulse: Rate -                   Regular/irregular - 
Character -                                     R/F delay - 
RR: 
---------------------------------------------------------------------------------------------------------------- 
JVP: 
Inspection and palpation: 
Chest wall- 
Apex-                                                                   
Parasternal pulsation-                         Epigastric pulsation-                     2nd left space- 
Palpable sounds- 
 
Thrill-  
 
Auscultation: 
S1-                                                                             S2- 
S3-                                                                             S4- 
Clicks -                                                                 Murmurs - 
ECG:                              
CXR: 
BIOCHEMISTRY: 
eGFR: 
Plasma NT-ProBNP 
 
 
xiv 
 
Echocardiography  
M-Mode and 2D:                                      
IVSd-                                                                        LVPWd-  
LVIDd-                                                                     LVIDs-   
FS:                       EDV (Teich):                      ESV (Teich):                      EF 
(Teich):      
                             EDV (Simp):                      ESV (Simp):                       EF (Simp): 
Etiolgy of aortic stenosis :  
Annulus -                           Sinuses-                   STJ -                              Asc.Ao - 
LVOT -  Diameter -                                                 Area -  
LA diameter -                                                     LA volume - 
LV mass -  
 
Doppler Measurements & TDI 
 
MV E max vel:                                          MV A max vel:  
 
MV E/A:                                              Decceleration time: 
Medial  e’:                                               Lateral e’ :                                           E/e: 
 
Aortic valve peak velocity (max. vel view):  
Aortic valve mean gradient(max. gdt view): 
AV VTI: 
LVOT VTI: 
Aortic valve area ( continuity equation): 
 
Global longitudinal strain (acquired by 2D):                             GLS by 4D:                 
Global circumferential strain (4D):                         Global area strain (4D): 
Global Radial strain (4D) 
 
xv 
 
Raw data spreadsheets 
 
S.No. I D Number Age Sex 
Symptom 
Status 
NYHA 
Class 
Syncope Angina 
CCS 
Class 
Diabetes HTN Smoking 
1 030371G 26 F Y 2 N N - N N N 
2 035188G 40 M Y 2 N N - Y N Y 
3 039834G 53 M Y 2 N N - N Y N 
4 042348G 69 M Y 3 Y Y 3 N Y N 
5 252598C 58 F N 1 N N - N N N 
6 048707G 65 M N 1 N N - Y Y Y 
7 388640D 63 M N 1 N N - Y N Y 
8 052887G 55 M Y 2 N N - N Y Y 
9 055340G 32 M N - N N - N N Y 
10 056485G 65 M Y 2 N N - Y N N 
11 976380A 32 M N - N N - N N N 
12 065458G 36 F N 1 N N - N N N 
13 422483D 74 M Y 2 N Y 2 N Y Y 
14 065312G 56 M Y 2 N Y 2 Y N Y 
15 093108G 39 M N 1 N N - N Y N 
16 134430G 72 M Y 2 N N - N N N 
17 138297G 50 F N 1 N N - N N N 
18 136491G 66 M Y 2 N N - N N N 
19 142243G 31 M N 1 N N - N N Y 
20 141984G 53 M Y 2 N Y 2 Y N Y 
21 047787G 50 F Y 2 N N - N N N 
22 146033G 54 M Y 3 N N - N N N 
23 146490G 70 M Y 2 N N - N N N 
24 149832G 64 F Y 2 N N - N N N 
25 855354B 54 M Y 2 N N - N N Y 
26 146622G 35 M Y 2 N N - N N N 
27 837185C 46 M N - N N - N N N 
28 147633G 55 M Y 2 N N - N Y Y 
29 131663G 56 M N - N N - N N N 
30 063870G 64 M Y 2 N Y 2 N Y Y 
31 946271F 77 M Y 2 N N - Y N N 
32 030215G 45 F N - N N - N N N 
33 166243G 49 M Y 2 N Y 2 Y Y N 
34 CONTROL 1 51 M - - - - - N N N 
35 CONTROL 2 26 M - - - - - N N N 
36 CONTROL 3 65 F - - - - - N N N 
37 CONTROL 4 38 F - - - - - N N N 
38 CONTROL 5 29 F - - - - - N N N 
39 CONTROL 6 29 M - - - - - N N N 
40 CONTROL 7 55 M - - - - - N N N 
41 CONTROL 8 44 M - - - - - N N N 
42 CONTROL 9 55 M - - - - - N N N 
43 
CONTROL 
10 
74 M - - - - - N N N 
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Raw data spreadsheets 
 
S.No. 
Height 
(Cm) 
Weight 
(Kg) 
BSA 
(m^2) 
BMI 
(kg/m^2) 
SBP 
(mmHg) 
DBP 
(mmHg) 
HR 
(bpm) 
Cr. Cl 
(ml/min) 
IVSd  
(cm) 
PWd 
(cm) 
LVEDD 
(cm) 
LVESD 
(cm) 
LVOT 
diamet
er (cm) 
1 148 53.5 1.46 24.40 94 74 89 102.0 1.4 1.4 3.5 2.4 1.7 
2 167 54.0 1.62 19.40 116 66 66 110.0 1.4 1.4 4.0 2.8 2.4 
3 160 80.0 1.83 31.20 148 84 74 80.0 1.4 1.5 4.6 3.0 2.1 
4 163 78.0 1.84 29.40 116 78 72 71.0 1.6 1.7 5.0 3.5 2.3 
5 141 45.0 1.31 22.60 138 84 84 73.0 0.9 0.9 4.1 2.7 1.9 
6 176 56.5 1.69 18.24 150 78 62 57.0 1.4 1.2 3.7 2.4 1.8 
7 171 73.0 1.84 24.60 120 70 88 94.0 1.0 1.0 4.1 2.5 2.0 
8 169 87.4 1.98 30.60 160 98 108 92.0 2.0 1.7 4.4 3.2 2.3 
9 170 76.9 1.88 26.61 124 82 106 124.0 1.6 1.6 3.8 2.4 2.2 
10 166 69.3 1.77 25.15 124 84 86 84.0 1.6 1.8 3.6 2.4 1.7 
11 176 60.3 1.74 19.47 100 58 66 123.0 1.1 0.9 4.6 3.0 2.1 
12 151 53.4 1.48 23.42 104 64 83 99.0 1.0 0.9 3.5 2.1 2.2 
13 163 78.0 1.84 29.36 142 62 59 36.0 1.9 1.9 4.4 2.8 2.1 
14 174 72.6 1.87 23.98 122 80 70 104.0 2.1 2.1 5.4 3.9 2.4 
15 174 75.3 1.90 24.87 148 75 69 90.0 1.2 1.2 4.0 1.6 2.0 
16 167 60.5 1.68 21.69 142 68 62 86.0 1.5 1.6 4.4 2.9 1.7 
17 166 72.5 1.81 26.31 120 72 88 110.0 1.6 1.4 3.5 2.1 1.8 
18 154 44.0 1.38 18.55 100 72 66 71.0 1.7 1.5 3.6 2.4 1.7 
19 171 61.0 1.71 20.86 94 62 68 99.0 1.4 1.5 3.8 2.1 2.1 
20 167 70.0 1.79 25.10 120 82 56 58.0 1.8 1.7 4.3 3.1 1.9 
21 150 40.0 1.30 17.78 110 70 57 54.0 1.6 1.4 4.2 2.8 1.9 
22 170 71.5 1.83 24.74 98 64 91 86.0 1.6 1.4 5.2 3.8 2.6 
23 162 56.5 1.60 21.53 132 86 69 83.0 1.5 1.4 2.9 1.8 1.8 
24 148 0.0 1.49 25.75 154 70 88 82.0 1.5 1.6 4.4 3.1 2.0 
25 168 55.0 1.62 19.49 160 74 73 73.0 1.6 1.6 4.3 2.8 2.0 
26 165 67.0 1.74 24.61 122 82 94 84.0 1.7 1.7 4.4 3.1 3.1 
27 174 74.2 1.89 24.51 112 84 79 98.0 1.1 1.1 4.2 2.9 2.0 
28 176 78.9 1.95 25.47 110 70 83 100.0 2.0 1.9 4.7 3.3 2.3 
29 164 70.5 1.77 26.21 125 85 65 74.0 1.1 1.1 3.3 2.0 1.9 
30 156 63.0 1.63 25.90 160 82 86 85.0 1.5 1.4 4.9 3.4 2.1 
31 156 55.8 1.54 22.90 124 62 79 51.6 1.2 1.2 4.8 3.5 2.0 
32 169 56.9 1.65 19.90 130 70 81 84.9 1.2 1.2 3.6 2.5 1.9 
33 160 93.3 1.96 36.40 160 80 93 90.6 1.2 1.4 3.8 2.6 2.2 
34 175 76.1 1.92 24.85 132 72 56 109.9 1.1 1.1 4.5 3.3 2.3 
35 132 82.0 1.61 47.06 130 74 81 121.0 0.8 0.8 4.9 3.2 2.4 
36 174 62.0 1.75 20.48 120 82 68 53.6 0.9 1.0 3.7 2.5 1.9 
37 152 64.5 1.61 27.92 130 72 97 67.0 0.7 0.8 4.0 2.7 1.8 
38 161 76.0 1.80 29.32 124 78 88 121.7 0.8 0.8 3.2 2.3 2.0 
39 174 64.5 1.78 21.30 130 80 86 128.6 0.9 0.9 4.2 2.9 2.0 
40 170 102.1 2.12 35.33 112 74 96 83.3 1.2 1.1 3.9 2.7 2.2 
41 161 59.8 1.63 23.07 110 70 68 76.3 1.0 0.9 3.6 2.2 1.8 
42 161 61.2 1.64 23.61 138 78 58 91.0 1.0 1.0 4.5 3.0 1.9 
43 160 60.2 1.62 23.52 136 82 62 50.6 1.2 1.2 3.9 2.7 2.2 
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Raw data spreadsheets 
 
S.No. 
LA volume 
index 
(ml/m^2) 
LV mass 
index 
(gm/m^2) 
EDV 
(ml) 
ESV 
(ml) 
EF (%) 
E vel 
(m/sec) 
A vel 
(m/sec) 
E/A 
Dec. time 
(msec) 
Medial 
e' 
(m/sec) 
E/e' Etiology 
1 29.0 113.5 56.0 22.0 60 1.31 0.79 1.65 267.00 0.07 18.46 BAV 
2 24.1 171.1 101.0 40.0 60 0.57 0.80 0.71 238.00 0.05 11.13 UK 
3 19.1 147.9 110.0 44.0 60 0.91 1.00 1.10 247.00 0.06 15.20 BAV 
4 26.1 202.4 96.0 42.0 56 0.59 1.07 0.55 260.00 0.02 29.50 ARC 
5 23.7 93.9 80.0 32.0 60 0.70 0.81 0.86 134.00 0.07 11.13 BAV 
6 19.0 94.1 59.0 22.0 63 0.60 0.81 0.74 290.00 0.05 1.00 ARC 
7 17.9 71.8 110.0 34.0 69 0.89 0.72 1.24 170.00 0.07 12.82 ARC 
8 38.2 164.5 128.0 59.0 54 0.30 1.26 0.24 70.00 0.02 15.27 UK 
9 18.7 101.1 75.0 31.0 59 1.05 0.81 0.81 141.00 0.06 16.98 BAV 
10 26.3 144.3 62.0 23.0 64 0.87 1.26 0.69 262.00 0.04 21.58 ARC 
11 35.9 90.9 113.0 36.0 68 1.61 1.64 0.98 468.00 0.05 32.55 RHD 
12 24.0 56.3 64.0 14.0 78 0.73 0.69 1.06 140.00 0.10 7.43 BAV 
13 40.7 163.0 124.0 38.0 69 0.72 1.13 0.64 219.00 0.03 25.23 ARC 
14 53.5 274.6 107.0 48.0 55 0.98 0.81 1.21 156.00 0.04 27.85 UK 
15 17.5 90.6 63.0 22.0 64 0.68 0.86 0.79 213.00 0.05 12.94 BAV 
16 27.8 152.6 83.0 29.0 65 0.94 0.85 1.11 161.00 0.03 30.75 ARC 
17 15.6 82.8 72.0 28.0 61 0.55 0.81 0.67 130.00 0.04 14.47 BAV 
18 33.3 143.2 59.0 15.0 74 0.81 0.77 1.06 178.00 0.04 19.57 ARC 
19 21.3 92.6 68.0 21.0 70 0.82 0.57 1.45 174.00 0.06 12.72 BAV 
20 35.3 201.3 72.0 34.0 52 0.78 0.73 1.07 153.00 0.03 23.09 ARC 
21 47.1 135.9 53.0 18.0 67 0.88 0.82 1.08 342.00 0.03 26.55 UK 
22 23.2 167.4 188.0 87.0 54 0.69 0.82 0.84 195.00 0.03 23.27 UK 
23 19.3 71.1 53.0 21.0 61 0.92 1.33 0.69 262.00 0.04 21.94 BAV 
24 32.0 194.8 107.0 41.0 61 0.50 1.48 0.34 235.00 0.03 17.09 ARC 
25 28.7 144.4 88.0 40.0 55 1.41 1.38 1.02 298.00 0.04 34.88 RHD 
26 20.1 144.1 160.0 68.0 58 0.76 0.87 0.88 187.00 0.05 15.21 BAV 
27 13.3 99.8 84.0 32.0 62 0.76 0.58 1.33 155.00 0.07 10.27 BAV 
28 35.8 181.7 118.0 44.0 63 1.62 1.03 1.58 172.00 0.03 53.93 BAV 
29 15.1 64.4 56.0 20.0 64 0.77 0.74 1.05 217.00 0.07 11.41 BAV 
30 18.0 182.2 124.0 52.0 58 0.59 1.02 0.58 195.00 0.05 11.81 ARC 
31 26.9 106.2 95.0 46.0 51 0.70 1.06 0.67 132.00 0.03 21.00 ARC 
32 18.6 71.1 36.0 16.0 56 0.50 0.76 0.67 247.00 0.04 11.48 BAV 
33 29.4 66.9 71.0 27.0 62 0.98 1.19 0.83 208.00 0.06 16.93 UK 
34 14.6 76.9 100.0 40.0 60 0.78 0.48 1.65 178.00 0.11 6.66 - 
35 26.7 86.1 106.0 36.0 66 0.60 0.35 1.72 177.00 0.12 5.00 - 
36 16.6 50.2 46.0 16.0 65 0.76 0.84 0.91 220.00 0.07 10.85 - 
37 14.9 49.3 55.0 20.0 64 0.84 0.67 1.27 161.00 0.09 9.33 - 
38 15.6 39.0 64.0 27.0 58 0.78 0.57 1.35 170.00 0.10 8.12 - 
39 18.5 72.5 74.0 32.0 56 0.97 0.51 1.91 183.00 0.14 7.10 - 
40 21.2 59.7 78.0 29.0 63 0.94 0.81 1.18 168.00 0.10 9.12 - 
41 19.0 58.0 62.0 20.0 68 0.83 0.73 1.14 199.00 0.08 10.23 - 
42 17.7 78.4 76.0 30.0 61 0.77 0.52 1.50 184.00 0.07 11.84 - 
43 27.8 78.4 78.0 29.0 63 0.76 0.84 0.90 220.00 0.08 9.50 - 
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Raw data spreadsheets 
 
S.No. 
Peak 
aortic 
velocity 
(m/sec) 
Mean 
gradient 
(mmHg) 
AV 
VTI 
(cm) 
LVOT 
VTI 
(cm) 
AVA 
(cm^2
) 
AVAi 
(cm^2/m
^2) 
GLS GCS GAS GRS 
Basal 
LS 
Apical 
LS 
NT-ProBNP 
(pg/ml) 
1 4.2 45.0 104.2 31.2 0.7 0.5 -14.1 -15.0 -26.0 38.0 -9.0 -20.4 1355.00 
2 4.8 58.0 106.0 18.6 0.8 0.5 -17.8 -21.0 -32.0 56.0 -5.2 -27.8 1118.60 
3 4.4 44.6 107.0 27.8 0.9 0.5 -10.0 -19.0 -27.0 40.0 -8.8 -13.2 535.20 
4 4.7 54.2 113.0 19.0 0.7 0.4 -8.1 -11.0 -19.0 20.0 -6.7 -12.6 2179.00 
5 3.2 28.0 79.7 34.3 1.2 0.9 -19.2 -22.0 -35.0 59.0 -15.8 -24.6 117.40 
6 3.9 36.9 84.0 20.3 0.7 0.4 -13.0 -14.0 -22.0 32.0 -10.2 -15.6 264.20 
7 3.5 28.0 76.0 31.4 1.3 0.7 -19.0 -22.0 -34.0 56.0 -15.2 -26.6 187.70 
8 4.7 57.3 100.1 16.4 0.7 0.4 -10.7 -11.0 -18.0 24.0 -6.2 -15.2 331.60 
9 4.4 46.9 71.5 19.4 1.0 0.5 -12.2 -16.0 -26.0 38.0 -8.8 -8.6 182.00 
10 4.4 44.0 76.7 29.9 0.9 0.5 -11.8 -19.0 -27.0 40.0 -5.2 -13.2 647.70 
11 3.4 27.3 76.5 27.5 1.2 0.7 -21.0 -18.0 -34.0 59.0 -20.0 -18.2 54.40 
12 3.7 30.6 72.9 25.6 1.3 0.9 -20.5 -20.0 -35.0 57.0 -17.2 -24.4 131.50 
13 5.5 77.6 137.0 26.0 0.7 0.4 -7.0 -15.0 -21.0 29.0 -1.5 -7.2 5603.00 
14 3.5 31.1 70.7 19.1 1.2 0.6 -9.3 -16.0 -25.0 35.0 -7.7 -7.0 6280.00 
15 4.2 40.2 91.4 23.8 0.8 0.4 -12.6 -19.0 -28.0 46.0 -8.5 -12.8 81.65 
16 5.9 94.7 155.4 23.8 0.3 0.2 -11.5 -15.0 -20.0 38.0 -12.3 -9.0 4764.00 
17 4.6 58.3 98.5 19.5 0.5 0.3 -14.4 -15.0 -27.0 40.0 -8.2 -21.0 151.50 
18 3.8 36.3 81.7 20.5 0.6 0.4 -13.0 -16.0 -24.0 36.0 -7.2 -16.4 1381.00 
19 4.1 40.5 82.1 19.9 0.8 0.5 -18.0 -23.0 -34.0 60.0 -14.2 -23.2 96.94 
20 4.6 51.1 103.8 25.0 0.7 0.4 -10.5 -12.0 -23.0 32.0 -5.7 -16.2 5361.00 
21 5.9 88.7 155.2 30.2 0.6 0.5 -12.6 -17.0 -25.0 41.0 -8.3 -12.8 4357.00 
22 4.8 56.6 95.2 17.3 0.9 0.5 -8.1 -11.0 -19.0 20.0 -2.2 -12.2 2141.00 
23 4.8 54.6 104.1 29.1 0.8 0.5 -15.0 -15.0 -25.0 38.0 -13.3 -16.4 163.40 
24 4.6 52.4 91.8 21.5 0.8 0.5 -11.6 -17.0 -26.0 40.0 -3.8 -18.8 453.40 
25 4.7 53.7 105.9 28.0 0.8 0.5 -14.5 -18.0 -28.0 43.0 -9.8 -19.8 1191.00 
26 5.6 89.1 142.7 14.6 0.8 0.5 -15.2 -18.0 -31.0 50.0 -10.5 -22.4 614.20 
27 3.3 25.3 67.5 26.3 1.3 0.7 -14.9 -16.0 -27.0 40.0 -9.2 -17.4 29.05 
28 5.2 67.9 133.3 19.0 0.6 0.3 -9.1 -14.0 -21.0 29.0 -6.7 -12.6 3332.00 
29 3.6 31.5 77.6 28.3 1.0 0.6 -20.5 -18.0 -31.0 48.0 -16.2 -24.6 120.40 
30 4.7 64.2 123.0 24.9 0.7 0.4 -9.9 -19.0 -27.0 40.0 -8.1 -13.6 194.20 
31 3.4 29.8 72.6 18.6 0.8 0.5 -13.5 -12.0 -20.0 27.0 -8.7 -18.8 846.00 
32 4.6 50.9 86.6 24.9 0.8 0.5 -13.5 -11.0 -20.0 28.0 -12.2 -16.2 70.66 
33 4.3 44.5 92.3 23.3 0.9 0.5 -15.2 -16.0 -23.0 34.0 -11.3 -16.2 195.20 
34 1.1 2.7 26.6 25.0 3.9 2.0 -19.8 -16.0 -28.0 41.0 -18.2 -22.0 13.30 
35 1.0 2.4 28.1 23.6 3.8 2.4 -22.8 -15.0 -32.0 50.0 -17.3 -29.2 22.33 
36 1.3 3.8 27.5 28.2 2.9 1.7 -23.4 -20.0 -35.0 59.0 -17.8 -31.8 79.85 
37 1.2 2.6 24.4 24.0 2.5 1.6 -18.7 -13.0 -26.0 40.0 -20.0 -18.6 23.04 
38 0.9 2.2 23.2 22.2 3.0 1.7 -20.9 -21.0 -34.0 58.0 -19.5 -23.0 13.32 
39 1.2 2.3 21.1 20.8 3.1 1.7 -19.5 -16.0 -31.0 49.0 -18.2 -22.2 69.61 
40 1.0 2.4 18.6 17.1 3.5 1.7 -20.6 -19.0 -26.0 40.0 -20.2 -21.8 30.03 
41 1.1 2.4 21.1 21.2 2.6 1.6 -20.0 -16.0 -34.0 57.0 -18.2 -22.2 39.24 
42 1.0 2.3 21.0 17.7 2.3 1.4 -20.2 -13.0 -26.0 38.0 -20.8 -21.8 39.38 
43 1.3 3.2 27.2 26.5 3.7 2.3 -21.8 -19.0 -32.0 57.0 -20.0 -21.2 80.82 
 
